KASID
Original article
- Page Path
- HOME > Article category > Original article
Original Articles
- Functional bowel disorders
- Evaluation of symptoms and symptom combinations in histamine intolerance
- Wolfgang J. Schnedl, Sonja Lackner, Dietmar Enko, Michael Schenk, Sandra J. Holasek, Harald Mangge
- Intest Res 2019;17(3):427-433. Published online March 7, 2019
- DOI: https://doi.org/10.5217/ir.2018.00152
-
Abstract
PDF
PubReader
ePub - Background/Aims
Food intolerance/malabsorption, particularly histamine intolerance (HIT), may cause nonspecific functional gastrointestinal and extraintestinal symptoms. We evaluated gastrointestinal and extraintestinal symptoms in patients with HIT.
Methods
In an analysis of outpatients’ charts we identified 133 patients, who presented with recurring nonspecific functional gastrointestinal, extraintestinal symptoms, and a diamine oxidase value <10 U/mL, indicative of HIT. A standardized anonymous questionnaire with symptoms of HIT based on known symptoms and the 4 histamine receptors including gastrointestinal, cardiovascular, respiratory and skin complaints was developed, and sent by mail to the patients.
Results
In the 62 patients that completed the questionnaire bloating was the most common and most serious symptom. Other commonly reported gastrointestinal symptoms were postprandial fullness, diarrhea, abdominal pain, and constipation. The presence of 2 from a list of 24 symptoms resulted in 276 various symptom combinations. From calculated 2.024 possible combinations of 3 symptoms the patients with HIT presented 1.975 combinations.
Conclusions
The knowledge of this wide variability of symptoms and complex symptom combinations in patients with HIT may help to clinically recognize and diagnose HIT. -
Citations
Citations to this article as recorded by
- Spectrum, Time Course, Stages, and a Proposal for the Diagnosis of Histamine Intolerance in General Practice: A Nonrandomized, Quasi-Experimental Study
József Tamasi, László Kalabay
Journal of Clinical Medicine.2025; 14(2): 311. CrossRef - Exploring the Relationship between Diamine Oxidase and Psychotropic Medications in Fibromyalgia Treatment, Finding No Reduction in Diamine Oxidase Levels and Activity except with Citalopram
Yaiza Tobajas, Marc Alemany-Fornés, Iris Samarra, Jordi Romero-Giménez, Jordi Cuñé-Castellana, Maria Tintoré, Antoni del Pino, Núria Canela, Josep M. del Bas, Nàdia Ortega-Olivé, Carlos de Lecea, Xavier Escoté
Journal of Clinical Medicine.2024; 13(3): 792. CrossRef - Nahrungsmittelallergie und Histaminintoleranz
Yurdagül Zopf, Walburga Dieterich
Die Gastroenterologie.2024; 19(1): 3. CrossRef - Prevalence and Clinical Picture of Diamine Oxidase Gene Variants in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Pilot Study
Hilario Blasco-Fontecilla, Marcos Bella-Fernández, Ping Wang, Marina Martin-Moratinos, Chao Li
Journal of Clinical Medicine.2024; 13(6): 1659. CrossRef - Histamine intolerance
Martin Fuchs
Medicína pro praxi.2024; 21(1): 18. CrossRef - Pilot Study on the Prevalence of Diamine Oxidase Gene Variants in Patients with Symptoms of Histamine Intolerance
Adriana Duelo, Oriol Comas-Basté, Sònia Sánchez-Pérez, M. Teresa Veciana-Nogués, Eva Ruiz-Casares, M. Carmen Vidal-Carou, M. Luz Latorre-Moratalla
Nutrients.2024; 16(8): 1142. CrossRef - Histamine Intolerance: Symptoms, Diagnosis, and Beyond
Christoph Jochum
Nutrients.2024; 16(8): 1219. CrossRef - Histamin İntoleransına Güncel Bakış
Yeşim Öztekin
İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2024; (22): 446. CrossRef - A Novel Herbal Composition Alleviates Functional Constipation, Reduces Gastrointestinal Transit Time, and Improves Bowel Function in Adults: A Double-Blind, Randomized Clinical Study
Gaurav Singh, Indresh Dixit, Douglas Kalman, Naga Tejaswi Gogineni
Journal of the American Nutrition Association.2024; 43(6): 553. CrossRef - Nutritional Implications of Mast Cell Diseases
Cheryl Iny Harris, Bonnie Nasar, Celeste C. Finnerty
Journal of the Academy of Nutrition and Dietetics.2024; 124(11): 1387. CrossRef - The Factors Influencing the Concentration of Histamine in Jarred Baby Foods Containing Fish, Considering Evaluation of Daily Histamine Intake
Marta Buczkowska, Anna Szczyrba, Dominika Szajnoga, Michał Górski, Jolanta Malinowska-Borowska, Joanna Domagalska, Piotr Rozentryt
Journal of Food Protection.2024; 87(9): 100328. CrossRef - A pathophysiological perspective on wine induced headaches
Greta Stołecka, Mateusz Sydor, Paulina Kalemba, Konrad Kochman, Robert Iwanowski, Paweł Iwaszkiewicz
Medical Journal of Cell Biology.2024; 12(3): 101. CrossRef - Cutaneous mastocytosis: diagnostic challenges and dietary influences in a prolonged case report
Lina Al-Soufi, Aya Marashli, Rahaf Chukri HajBakri, Zuheir Al-Shehabi
Dermatology Reports.2024;[Epub] CrossRef - Study Protocol for a Prospective, Unicentric, Double-Blind, Randomized, and Placebo-Controlled Trial on the Efficacy of a Low-Histamine Diet and DAO Enzyme Supplementation in Patients with Histamine Intolerance
Adriana Duelo, Sònia Sánchez-Pérez, Ana Ruiz-Leon, Francesc Casanovas-Garriga, Salvador Pellicer-Roca, Irache Iduriaga-Platero, Judit Costa-Catala, M. Veciana-Nogués, Joaquim Fernández-Solà, Rosa Muñoz-Cano, Joan Bartra, Andrea Combalia, Oriol Comas-Basté
Nutrients.2024; 17(1): 29. CrossRef - Trans-ε-viniferin as an inhibitor of TMEM16A preventing intestinal smooth muscle contraction
Xin-Yi Liu, Yan Zhao, Ling-Ling Jin, Yue Pang, Bo Yu
Journal of Asian Natural Products Research.2023; 25(9): 867. CrossRef - Focus on histamine production during cheese manufacture and processing: A review
Maria Carmela Ferrante, Raffaelina Mercogliano
Food Chemistry.2023; 419: 136046. CrossRef - Cumulative effect of AOC1 gene variants on symptoms and pathological conditions in adult women with fibromyalgia: a pilot study
Gülşah Okutan, Teresa Perucho Alcalde, Eva Ruiz Casares, Bruno F. Penadés, Guerthy Melissa Sánchez Niño, Ana Terrén Lora, Sara López Oliva, Lorena Torrente Estríngana, Adriana Duelo, Ismael San Mauro Martín
Frontiers in Genetics.2023;[Epub] CrossRef - Food Fermentation Technology: Examples of application in Malaysian Foods
Genevie Eleanor Ruby, Noor Azira Abdul Mutalib, Nurul Hanisah Juhari, Ungku Fatimah Ungku Zainal Abidin
Food and Humanity.2023; 1: 32. CrossRef - Histamine intolerance and irritable bowel syndrome
Yu.A. Golubeva, A.F. Sheptulina, O.M. Drapkina
Profilakticheskaya meditsina.2023; 26(6): 130. CrossRef - Functional Abdominal Pain Disorders in Children May Be Associated with Food Intolerance/Malabsorption
Wolfgang J. Schnedl, Michael Schenk, Simon Michaelis, Dietmar Enko, Harald Mangge
Children.2023; 10(9): 1444. CrossRef - Resistant potato starch supplementation reduces serum histamine levels in healthy adults with links to attenuated intestinal permeability
Jason R. Bush, Jun Han, Edward C. Deehan, Scott V. Harding, Madhura Maiya, Joshua Baisley, David Schibli, David R. Goodlett
Journal of Functional Foods.2023; 108: 105740. CrossRef - Placebo-Controlled Histamine Challenge Disproves Suspicion of Histamine Intolerance
Rebekka Karolin Bent, Claudia Kugler, Valentina Faihs, Ulf Darsow, Tilo Biedermann, Knut Brockow
The Journal of Allergy and Clinical Immunology: In Practice.2023; 11(12): 3724. CrossRef - Exogenous Supplementation with DAO Enzyme in Women with Fibromyalgia: A Double-Blind Placebo-Controlled Clinical Trial
Gülşah Okutan, Guerthy Melissa Sánchez Niño, Ana Terrén Lora, Sara López Oliva, Ismael San Mauro Martín
Journal of Clinical Medicine.2023; 12(20): 6449. CrossRef - Diet of the 21st-century person — food intolerances and elimination diets
Ewa Gacoń
Health Promotion & Physical Activity.2023; 23(2): 21. CrossRef - Health concerns associated with biogenic amines in food and interaction with amine oxidase drugs
Bruno M Dala-Paula, Flávia B Custódio, Maria BA Gloria
Current Opinion in Food Science.2023; 54: 101090. CrossRef - Myths and Facts about Food Intolerance: A Narrative Review
Fabiana Zingone, Luisa Bertin, Daria Maniero, Michela Palo, Greta Lorenzon, Brigida Barberio, Carolina Ciacci, Edoardo Vincenzo Savarino
Nutrients.2023; 15(23): 4969. CrossRef - Diamine Oxidase Interactions with Anti-Inflammatory and Anti-Migraine Medicines in the Treatment of Migraine
Yaiza Tobajas, Marc Alemany-Fornés, Iris Samarra, Jordi Romero-Giménez, Maria Tintoré, Antoni del Pino, Núria Canela, Josep M. del Bas, Nàdia Ortega-Olivé, Carlos de Lecea, Xavier Escoté
Journal of Clinical Medicine.2023; 12(23): 7502. CrossRef - Nachblutung bei Septorhinoplastik
Olaf Michel
HNO Nachrichten.2023; 53(6): 35. CrossRef - Intolerancia alimentaria
Mauricio Colella, Claudio Alberto Salvador Parisi
Revista Alergia México.2023; 70(4): 265. CrossRef - Diagnóstico diferencial en alergia alimentaria
Liziane Nunes de Castilho Santos
Revista Alergia México.2023; 70(4): 260. CrossRef - Food allergy and hypersensitivity reactions in children and adults—A review
Sandra G. Tedner, Anna Asarnoj, Helena Thulin, Marit Westman, Jon R. Konradsen, Caroline Nilsson
Journal of Internal Medicine.2022; 291(3): 283. CrossRef - Histamine Intolerance—A Kind of Pseudoallergic Reaction
Ying Zhao, Xiaoyan Zhang, Hengxi Jin, Lu Chen, Jiang Ji, Zhongwei Zhang
Biomolecules.2022; 12(3): 454. CrossRef - Food intolerances and the small intestine
Asfold I. Parfenov
Terapevticheskii arkhiv.2022; 94(2): 153. CrossRef - Basal Serum Diamine Oxidase Levels as a Biomarker of Histamine Intolerance: A Retrospective Cohort Study
Valentina Cucca, Giuseppe A. Ramirez, Patrizia Pignatti, Chiara Asperti, Marco Russo, Emanuel Della-Torre, Daniela Breda, Samuele E. Burastero, Lorenzo Dagna, Mona-Rita Yacoub
Nutrients.2022; 14(7): 1513. CrossRef - Intestinal Dysbiosis in Patients with Histamine Intolerance
Sònia Sánchez-Pérez, Oriol Comas-Basté, Adriana Duelo, M. Teresa Veciana-Nogués, Mercedes Berlanga, M. Luz Latorre-Moratalla, M. Carmen Vidal-Carou
Nutrients.2022; 14(9): 1774. CrossRef - Serum Diamine Oxidase Values, Indicating Histamine Intolerance, Influence Lactose Tolerance Breath Test Results
Wolfgang J. Schnedl, Nathalie Meier-Allard, Simon Michaelis, Sonja Lackner, Dietmar Enko, Harald Mangge, Sandra J. Holasek
Nutrients.2022; 14(10): 2026. CrossRef - WITHDRAWN: Elevated histamine etiology model for most major vaccine associated adverse events including SARS-CoV-2 spike vaccines
Darrell O. Ricke
Medical Hypotheses.2022; : 110893. CrossRef - Histamine intolerance (HIT)
Joanna Matysiak
Journal of Medical Science.2022; : e727. CrossRef - The dietary treatment of histamine intolerance reduces the abundance of some histamine-secreting bacteria of the gut microbiota in histamine intolerant women. A pilot study
Sònia Sánchez-Pérez, Oriol Comas-Basté, Adriana Duelo, M. Teresa Veciana-Nogués, Mercedes Berlanga, M. Carmen Vidal-Carou, M. Luz Latorre-Moratalla
Frontiers in Nutrition.2022;[Epub] CrossRef - Advances in the Clinical Application of Histamine and Diamine Oxidase (DAO) Activity: A Review
Zhaowang Tan, Yingwei Ou, Wenwei Cai, Yueliang Zheng, Hengjie Li, Yunyun Mao, Shengang Zhou, Jianfeng Tu
Catalysts.2022; 13(1): 48. CrossRef - Improvement of digestive symptoms in fibromyalgia patients following a diet modification according to histamine release test – an observational study
Jose Gomez-Arguelles, Oscar Caceres, Manuel Blanco, Ceferino Maestu, Francisco Martin
Rheumatology.2022; 60(3): 209. CrossRef - Considering histamine in functional gastrointestinal disorders
Wolfgang J. Schnedl, Dietmar Enko
Critical Reviews in Food Science and Nutrition.2021; 61(17): 2960. CrossRef - Non-responsive celiac disease may coincide with additional food intolerance/malabsorption, including histamine intolerance
Wolfgang J. Schnedl, Harald Mangge, Michael Schenk, Dietmar Enko
Medical Hypotheses.2021; 146: 110404. CrossRef - Histamine accumulation in dairy products: Microbial causes, techniques for the detection of histamine‐producing microbiota, and potential solutions
Marta Moniente, Diego García‐Gonzalo, Ignacio Ontañón, Rafael Pagán, Laura Botello‐Morte
Comprehensive Reviews in Food Science and Food Safety.2021; 20(2): 1481. CrossRef - Histamine Intolerance Originates in the Gut
Wolfgang J. Schnedl, Dietmar Enko
Nutrients.2021; 13(4): 1262. CrossRef - Low-Histamine Diets: Is the Exclusion of Foods Justified by Their Histamine Content?
Sònia Sánchez-Pérez, Oriol Comas-Basté, M. Teresa Veciana-Nogués, M. Luz Latorre-Moratalla, M. Carmen Vidal-Carou
Nutrients.2021; 13(5): 1395. CrossRef - Histamine Intolerance in Children: A Narrative Review
Wojciech Nazar, Katarzyna Plata-Nazar, Katarzyna Sznurkowska, Agnieszka Szlagatys-Sidorkiewicz
Nutrients.2021; 13(5): 1486. CrossRef - Food Allergy and Intolerance: A Narrative Review on Nutritional Concerns
Domenico Gargano, Ramapraba Appanna, Antonella Santonicola, Fabio De Bartolomeis, Cristiana Stellato, Antonella Cianferoni, Vincenzo Casolaro, Paola Iovino
Nutrients.2021; 13(5): 1638. CrossRef - Food Intolerance: The Role of Histamine
Yulia O. Shulpekova, Vladimir M. Nechaev, Irina R. Popova, Tatiana A. Deeva, Arthur T. Kopylov, Kristina A. Malsagova, Anna L. Kaysheva, Vladimir T. Ivashkin
Nutrients.2021; 13(9): 3207. CrossRef - The cold chain and the COVID-19 pandemic: an unusual increase in histamine content in fish samples collected in Southern Italy during lockdown
Francesco Giuseppe Galluzzo, Gaetano Cammilleri, Antonello Cicero, Licia Pantano, Andrea Pulvirenti, Andrea Macaluso, Nicola Cicero, Vittorio Calabrese, Vincenzo Ferrantelli
Food Quality and Safety.2021;[Epub] CrossRef - Comparing histamine intolerance and non-clonal mast cell activation syndrome
Nevio Cimolai
Intestinal Research.2020; 18(1): 134. CrossRef - Lyophilised legume sprouts as a functional ingredient for diamine oxidase enzyme supplementation in histamine intolerance
Oriol Comas-Basté, M. Luz Latorre-Moratalla, Judit Rabell-González, M. Teresa Veciana-Nogués, M. Carmen Vidal-Carou
LWT.2020; 125: 109201. CrossRef - Histamine Intolerance: The Current State of the Art
Oriol Comas-Basté, Sònia Sánchez-Pérez, Maria Teresa Veciana-Nogués, Mariluz Latorre-Moratalla, María del Carmen Vidal-Carou
Biomolecules.2020; 10(8): 1181. CrossRef - Increasing Expiratory Hydrogen in Lactose Intolerance Is Associated with Additional Food Intolerance/Malabsorption
Wolfgang J. Schnedl, Nathalie Meier-Allard, Sonja Lackner, Dietmar Enko, Harald Mangge, Sandra J. Holasek
Nutrients.2020; 12(12): 3690. CrossRef - Interdisciplinary Significance of Food-Related Adverse Reactions in Adulthood
Dóra Solymosi, Miklós Sárdy, Györgyi Pónyai
Nutrients.2020; 12(12): 3725. CrossRef - Vegetal diamine oxidase alleviates histamine-induced contraction of colonic muscles
Armelle Tchoumi Neree, Rodolphe Soret, Lucia Marcocci, Paola Pietrangeli, Nicolas Pilon, Mircea Alexandru Mateescu
Scientific Reports.2020;[Epub] CrossRef - Diamine oxidase supplementation improves symptoms in patients with histamine intolerance
Wolfgang J. Schnedl, Michael Schenk, Sonja Lackner, Dietmar Enko, Harald Mangge, Florian Forster
Food Science and Biotechnology.2019; 28(6): 1779. CrossRef - Food Intolerances
Caroline J Tuck, Jessica R Biesiekierski, Peter Schmid-Grendelmeier, Daniel Pohl
Nutrients.2019; 11(7): 1684. CrossRef
- Spectrum, Time Course, Stages, and a Proposal for the Diagnosis of Histamine Intolerance in General Practice: A Nonrandomized, Quasi-Experimental Study
- 16,681 View
- 560 Download
- 49 Web of Science
- 58 Crossref
- Functional bowel disorders
- Is stool frequency associated with the richness and community composition of gut microbiota?
- Hye Jung Kwon, Jong Hyun Lim, Dongmin Kang, Sanghyun Lim, Seun Ja Park, Jae Hyun Kim
- Intest Res 2019;17(3):419-426. Published online February 7, 2019
- DOI: https://doi.org/10.5217/ir.2018.00149
-
Abstract
PDF
Supplementary MaterialPubReaderePub - Background/Aims
Recently, a number of studies have reported that the gut microbiota could contribute to human conditions, including obesity, inflammation, cancer development, and behavior. We hypothesized that the composition and distribution of gut microbiota are different according to stool frequency, and attempted to identify the association between gut microbiota and stool frequency.
Methods
We collected fecal samples from healthy individuals divided into 3 groups according to stool frequency: group 1, a small number of defecation (≤2 times/wk); group 2, normal defecation (1 time/day or 1 time/2 day); and group 3, a large number of defecation (≥2–3 times/day). We evaluated the composition and distribution of the gut microbiota in each group via 16S rRNA-based taxonomic profiling of the fecal samples.
Results
Fecal samples were collected from a total of 60 individuals (31 men and 29 women, aged 34.1±5.88 years), and each group comprised 20 individuals. The microbial richness of group 1 was significantly higher than that of group 3 and tended to decrease with increasing number of defecation (P<0.05). The biological community composition was fairly different according to the number of defecation, and Bacteroidetes to Firmicutes ratio was higher in group 1 than in the other groups. Moreover, we found specific strains at the family and genus levels in groups 1 and 3.
Conclusions
Bacteroidetes to Firmicutes ratio and the abundance of Bifidobacterium were different according to the stool frequency, and specific bacteria were identified in the subjects with large and small numbers of defecation, respectively. These findings suggest that stool frequency might be associated with the richness and community composition of the gut microbiota. -
Citations
Citations to this article as recorded by- Personalized probiotic strategy considering bowel habits: impacts on gut microbiota composition and alleviation of gastrointestinal symptoms via Consti-Biome and Sensi-Biome
Uigi Min, Yoo-Jeong Jin, You Jin Jang, Jonghyun Lim, Byung-Yong Kim
Frontiers in Nutrition.2024;[Epub] CrossRef - Deciphering the Impact of Defecation Frequency on Gut Microbiome Composition and Diversity
Gwoncheol Park, Seongok Kim, WonJune Lee, Gyungcheon Kim, Hakdong Shin
International Journal of Molecular Sciences.2024; 25(9): 4657. CrossRef - Advancing human gut microbiota research by considering gut transit time
Nicola Procházková, Gwen Falony, Lars Ove Dragsted, Tine Rask Licht, Jeroen Raes, Henrik M Roager
Gut.2023; 72(1): 180. CrossRef - Gut Microbiome Analysis for Personalized Nutrition: The State of Science
Marie‐Christine Simon, Christian Sina, Paola G. Ferrario, Hannelore Daniel
Molecular Nutrition & Food Research.2023;[Epub] CrossRef - The gut-microbiota-brain axis in a Spanish population in the aftermath of the COVID-19 pandemic: microbiota composition linked to anxiety, trauma, and depression profiles
Stefanie Malan-Müller, Mireia Valles-Colomer, Tomás Palomo, Juan C. Leza
Gut Microbes.2023;[Epub] CrossRef - Fecal microbiota transplantation in Parkinson's disease—A randomized repeat-dose, placebo-controlled clinical pilot study
Herbert L. DuPont, Jessika Suescun, Zhi-Dong Jiang, Eric L. Brown, Heather T. Essigmann, Ashley S. Alexander, Andrew W. DuPont, Tehseen Iqbal, Netanya S. Utay, Michael Newmark, Mya C. Schiess
Frontiers in Neurology.2023;[Epub] CrossRef - Effect of Probiotic-Fortified Infant Formula on Infant Gut Health and Microbiota Modulation
Ju Young Eor, Chul Sang Lee, Sung Ho Moon, Ju Young Cheon, Duleepa Pathiraja, Byeonghyeok Park, Min Jae Shin, Jae-Young Kim, Sangjong Kim, Youngbae Noh, Yunhan Kim, In-Geol Choi, Sae Hun Kim
Food Science of Animal Resources.2023; 43(4): 659. CrossRef - Efficacy of washed microbiota transplantation for therapeutic targets of refractory functional constipation and the influencing factors: a single-center, retrospective, 24-week follow-up study
Liquan Wu, Qingfen Yuan, Lihao Wu, Harry Hua-Xiang Xia, Muxiao Zhong, Tao Liu, Xiaoyan Ye, Danping Luo, Jiating Xu, Wenrui Xie, Xingxiang He, Jieyi Cai
BMC Gastroenterology.2023;[Epub] CrossRef - Scarring the early-life microbiome: its potential life-long effects on human health and diseases
Hyunji Park, Na-Young Park, Ara Koh
BMB Reports.2023; 56(9): 469. CrossRef - Frequency of Bowel Movements and Risk of Diverticulitis
Manol Jovani, Wenjie Ma, Kyle Staller, Amit D. Joshi, Po-Hong Liu, Long H. Nguyen, Paul Lochhead, Yin Cao, Idy Tam, Kana Wu, Edward L. Giovannucci, Lisa L. Strate, Andrew T. Chan
Clinical Gastroenterology and Hepatology.2022; 20(2): 325. CrossRef - Association Between Gastrointestinal Symptoms and Depression in a Representative Sample of Adults in the United States: Findings From National Health and Nutrition Examination Survey (2005–2016)
Sarah J. Eustis, Michael W. McCall, E. Angela Murphy, Michael D. Wirth
Journal of the Academy of Consultation-Liaison Psychiatry.2022; 63(3): 268. CrossRef - Effects of probiotics on cognitive and emotional functions in healthy older adults: Protocol for a double‐blind randomized placebo‐controlled crossover trial
Cristofer Ruiz‐Gonzalez, Diana Cardona, Miguel Rodriguez‐Arrastia, Carmen Ropero‐Padilla, Lola Rueda‐Ruzafa, Francisca Carvajal, Nuria Sanchez‐Labraca, Adrian Aparicio Mota, Pablo Roman
Research in Nursing & Health.2022; 45(3): 274. CrossRef - Diet and Gut Microbiome and the “Chicken or Egg” Problem
Hannelore Daniel
Frontiers in Nutrition.2022;[Epub] CrossRef - Proposal of a health gut microbiome index based on a meta-analysis of Korean and global population datasets
Hyun-Seok Oh, Uigi Min, Hyejin Jang, Namil Kim, Jeongmin Lim, Mauricio Chalita, Jongsik Chun
Journal of Microbiology.2022; 60(5): 533. CrossRef - Physical Complaints Decrease after Following a Few-Foods Diet in Children with ADHD
Lidy Pelsser, Tim Stobernack, Klaas Frankena
Nutrients.2022; 14(15): 3036. CrossRef - Differences in gut microbiota correlate with symptoms and regional brain volumes in patients with late-life depression
Chia-Fen Tsai, Chia-Hsien Chuang, Yen-Po Wang, Ya-Bo Lin, Pei-Chi Tu, Pei-Yi Liu, Po-Shan Wu, Chung-Yen Lin, Ching-Liang Lu
Frontiers in Aging Neuroscience.2022;[Epub] CrossRef - A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition
Bernadeta Pietrzak, Katarzyna Tomela, Agnieszka Olejnik-Schmidt, Łukasz Galus, Jacek Mackiewicz, Mariusz Kaczmarek, Andrzej Mackiewicz, Marcin Schmidt
Cancers.2022; 14(21): 5369. CrossRef - Nutritional, Health and Lifestyle Status of a Highly Physically Active and Health-Conscious Long-Term Vegan Man: A Case Report from Slovenia
Boštjan Jakše, Stanislav Pinter
Reports.2022; 5(4): 45. CrossRef - Self-Perception of Changes in Routines in Adults and Older Adults Associated to Social Distancing Due to COVID-19—A Study in São Paulo, Brazil
Adriana Machado-Lima, Angélica Castilho Alonso, Débora Gozzo, Gisele Garcia Zanca, Guilherme Carlos Brech, José Maria Montiel, Marta Ferreira Bastos, Priscila Larcher Longo, Sandra Regina Mota-Ortiz
Frontiers in Psychology.2021;[Epub] CrossRef - Changes in gut microbiota in the acute phase after spinal cord injury correlate with severity of the lesion
Gabriele Bazzocchi, Silvia Turroni, Maria Chiara Bulzamini, Federica D’Amico, Angelica Bava, Mirco Castiglioni, Valentina Cagnetta, Ernesto Losavio, Maurizio Cazzaniga, Laura Terenghi, Luisa De Palma, Giuseppina Frasca, Beatrice Aiachini, Sonia Cremascoli
Scientific Reports.2021;[Epub] CrossRef - Stool pattern is associated with not only the prevalence of tumorigenic bacteria isolated from fecal matter but also plasma and fecal fatty acids in healthy Japanese adults
Daiki Watanabe, Haruka Murakami, Harumi Ohno, Kumpei Tanisawa, Kana Konishi, Kikue Todoroki-Mori, Yuta Tsunematsu, Michio Sato, Yuji Ogata, Noriyuki Miyoshi, Naoto Kubota, Jun Kunisawa, Keiji Wakabayashi, Tetsuya Kubota, Kenji Watanabe, Motohiko Miyachi
BMC Microbiology.2021;[Epub] CrossRef - Shifts in the Fecal Microbial Community of Cystoisospora suis Infected Piglets in Response to Toltrazuril
Aruna Shrestha, Barbara U. Metzler-Zebeli, Hamadi Karembe, Daniel Sperling, Simone Koger, Anja Joachim
Frontiers in Microbiology.2020;[Epub] CrossRef - Diet and the gut microbiome: from hype to hypothesis
Hannelore Daniel
British Journal of Nutrition.2020; 124(6): 521. CrossRef - The Microbiota Profile in Inflamed and Non-Inflamed Ileal Pouch–Anal Anastomosis
Sabrina Just Kousgaard, Thomas Yssing Michaelsen, Hans Linde Nielsen, Karina Frahm Kirk, Mads Albertsen, Ole Thorlacius-Ussing
Microorganisms.2020; 8(10): 1611. CrossRef
- Personalized probiotic strategy considering bowel habits: impacts on gut microbiota composition and alleviation of gastrointestinal symptoms via Consti-Biome and Sensi-Biome
- 12,195 View
- 255 Download
- 25 Web of Science
- 24 Crossref
- Endoscopy
- Clinical comparison of low-volume agents (oral sulfate solution and sodium picosulfate with magnesium citrate) for bowel preparation: the EASE study
- Jeeyeon Kim, Hyun Gun Kim, Kyeong Ok Kim, Hyung Wook Kim, Jongha Park, Jeong-Sik Byeon, Sung-Wook Hwang, Hyun Deok Shin, Jeong Eun Shin, Hyo-Joon Yang, Hyun Seok Lee, Yunho Jung, Young-Seok Cho, Young Eun Joo, Dae-Seong Myung, Kyu Chan Huh, Eu Mi Ahn
- Intest Res 2019;17(3):413-418. Published online April 8, 2019
- DOI: https://doi.org/10.5217/ir.2018.00156
-
Abstract
PDFPubReaderePub
- Background/Aims
This study compared the efficacy, compliance, and safety of bowel preparation between sodium picosulfate with magnesium citrate (SPMC) and oral sulfate solution (OSS).
Methods
A prospective randomized multicenter study was performed. Split preparation methods were performed in both groups; the SPMC group, 2 sachets on the day before, and 1 sachet on the day of the procedure, the OSS group, half of the OSS with 1 L of water on both the day before and the day of the procedure. The adenoma detection rate (ADR), adequacy of bowel preparation using the Boston Bowel Preparation Scale (BBPS) score, patient satisfaction on a visual analog scale (VAS), and safety were compared between the 2 groups.
Results
This study analyzed 229 patients (121 in the SPMC group and 108 in the OSS group). ADR showed no differences between 2 groups (51.7% vs. 41.7%, P> 0.05). The mean total BBPS score (7.95 vs. 8.11, P> 0.05) and adequate bowel preparation rate (94.9% vs. 96.3%, P> 0.05) were similar between the 2 groups. The mean VAS score for taste (7.62 vs. 6.87, P=0.006) was significantly higher in the SPMC group than in the OSS group. There were no significant differences in any other safety variables between the 2 groups except nausea symptom (36.1% vs. 20.3%, P=0.008).
Conclusions
Bowel preparation for colonoscopy using low volume OSS and SPMC yielded similar ADRs and levels of efficacy. SPMC had higher levels of satisfaction for taste and feeling than did OSS. -
Citations
Citations to this article as recorded by- Comments on Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial
Ji Eun Kim
Gut and Liver.2024; 18(1): 192. CrossRef - Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial
Ji Min Lee, Kang-Moon Lee, Ho Suk Kang, Ja Seol Koo, Hyun Seok Lee, Seok-Hoo Jeong, Jung Ho Kim, Dae Bum Kim
Gut and Liver.2023; 17(4): 591. CrossRef - Quality indicators in colonoscopy: the chasm between ideal and reality
Su Bee Park, Jae Myung Cha
Clinical Endoscopy.2022; 55(3): 332. CrossRef - Comparison of the efficacy and safety between oral sulfate tablet and polyethylene glycol for bowel preparation before colonoscopy according to age
Jae Hyun Kim, Yong Eun Park, Tae Oh Kim, Jongha Park, Gyu Man Oh, Won Moon, Seun Ja Park
Medicine.2022; 101(27): e29884. CrossRef - Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: A multicentre randomized controlled study
Kyeong Ok Kim, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Eun Soo Kim, Yun Jin Chung, Byung Ik Jang, Sung Kook Kim, Chang Heon Yang
Journal of Crohn's and Colitis.2022; 16(11): 1706. CrossRef - Comparison of Two Types of 1-L Polyethylene Glycol-ascorbic Acid as Colonoscopic Bowel Preparation: A Prospective Randomized Study
Suh Hyun Choi, Won Eui Yoon, Seung Hyuk Kim, Hee Jun Myung, Seo Hyun Kim, Soon Oh So, Se Hun Kim, Hyun Mi Lee, Yeoun Jung Oh, Jeong Seop Moon, Tae Yeong Park, You Sun Kim
The Korean Journal of Gastroenterology.2022; 80(2): 85. CrossRef - Correlation between Surrogate Quality Indicators for Adenoma Detection Rate and Adenoma Miss Rate in Qualified Colonoscopy, CORE Study: KASID Multicenter Study
Jae Hee Han, Hyun Gun Kim, Eu Mi Ahn, Suyeon Park, Seong Ran Jeon, Jae Myung Cha, Min Seob Kwak, Yunho Jung, Jeong Eun Shin, Hyun Deok Shin, Young-Seok Cho
Gut and Liver.2022; 16(5): 716. CrossRef - How to Choose the Optimal Bowel Preparation Regimen for Colonoscopy
Ji Eun Na, Eun Ran Kim
The Ewha Medical Journal.2021; 44(4): 122. CrossRef - Optimal Laxatives for Oral Colonoscopy Bowel Preparation: from High-volume to Novel Low-volume Solutions
Soo-Young Na, Won Moon
The Korean Journal of Gastroenterology.2020; 75(2): 65. CrossRef - No inferioridad entre dos agentes de bajo volumen (Picosulfato de Sodio/Citrato de Magnesio vs. Sulfato de Sodio/Potasio/Magnesio) en la preparación de colon para procedimientos diagnósticos: estudio observacional
Erika D. Pérez-Riveros, Margarita Rey R., Belén Mendoza De Molano, Juan Carlos Robayo, Jaime Solano Mariño, Rafael García Duperly, Andrés Gómez, Renzo Pinto Carta, Gerardo Ardila, Jose De la Hoz-Valle, Fernando Sierra-Arango
Revista Colombiana de Gastroenterología.2020; 35(4): 436. CrossRef
- Comments on Oral Sulfate Solution Is as Effective as Polyethylene Glycol with Ascorbic Acid in a Split Method for Bowel Preparation in Patients with Inactive Ulcerative Colitis: A Randomized, Multicenter, and Single-Blind Clinical Trial
- 7,966 View
- 257 Download
- 9 Web of Science
- 10 Crossref
- Colorectal neoplasia
- Association of visceral adiposity and insulin resistance with colorectal adenoma and colorectal cancer
- In Sub Jung, Cheol Min Shin, Sung Jae Park, Young Soo Park, Hyuk Yoon, Hyun Jin Jo, Nayoung Kim, Dong Ho Lee
- Intest Res 2019;17(3):404-412. Published online November 12, 2018
- DOI: https://doi.org/10.5217/ir.2018.00072
-
Abstract
PDFPubReaderePub
- Background/Aims
To examine whether visceral adiposity serves as a risk factor for colorectal cancer (CRC) and colorectal adenomas.
Methods
Two hundred healthy subjects, 200 patients with colorectal adenoma, and 151 patients with CRC (46 with early-stage and 105 with advanced-stage cancers) were enrolled at a tertiary referral hospital. All subjects underwent colonoscopy, and had laboratory data, and computed tomography (CT) scan available for abdominal fat measurement. An abdominal CT scan taken 1 to 4 years (mean interval, 20.6 months) before the diagnosis of CRC was also available in the 42 CRC patients.
Results
The mean areas of visceral adipose tissue (VAT) areas in the control, adenoma, early- and advanced-stage CRC groups were 94.6, 116.8, 110.4, and 99.7 cm2 , respectively (P<0.001). The risk of adenoma positively correlated with VAT area and the visceral-to-total fat ratio (P for trend <0.01), but the risk of CRC did not (P>0.05). The risk of both adenoma and CRC positively correlated with fasting plasma glucose levels (P for trend <0.05). In patients with early-stage cancer (n=17), VAT area decreased when the CT scan at diagnosis was compared with that taken before the diagnosis of CRC, but superficial adipose tissue area did not, so visceral-to-total fat ratio significantly decreased (46.6% vs. 50.7%, respectively, P=0.018)
Conclusions
VAT area is related to the risk of colorectal adenoma. However, VAT decreases from the early stages of CRC. Impaired fasting glucose has a role in colorectal carcinogenesis. -
Citations
Citations to this article as recorded by- Change in abdominal obesity after colon cancer surgery – effects of left-sided and right-sided colonic resection
Younes Kays Mohammed Ali, Troels Gammeltoft Dolin, Janus Damm Nybing, Jakob Lykke, Frederik Hvid Linden, Erik Høgh-Schmidt, Thorkild I. A. Sørensen, Jesper Frank Christensen, Yousef J. W. Nielsen, Jim Stenfatt Larsen, Sten Madsbad, Julia Sidenius Johansen
International Journal of Obesity.2024; 48(4): 533. CrossRef - Research Progress on the Correlation between Metabolic Syndrome and Colorectal Polyps
欣然 王
Advances in Clinical Medicine.2024; 14(03): 1733. CrossRef - MAFLD with central obesity is associated with increased risk of colorectal adenoma and high-risk adenoma
Jingfang Xiong, Yijun Wu, Dongya Chen, Zhaolin Zhang, Yihui Liu, Jiandong Luo, Hong Xu
BMC Gastroenterology.2024;[Epub] CrossRef - Association between Atherosclerosis and High-Risk Colorectal Adenomas based on Cardio-Ankle Vascular Index and Ankle-Brachial Index
Jung Ho Lee, Hyunseok Cho, Sang Hoon Lee, Sung Joon Lee, Chang Don Kang, Dae Hee Choi, Jin Myung Park, Seung-Joo Nam, Tae Suk Kim, Ji Hyun Kim, Sung Chul Park
The Korean Journal of Gastroenterology.2024; 83(4): 143. CrossRef - Hot Spots and Trends in the Relationship between Cancer and Obesity: A Systematic Review and Knowledge Graph Analysis
Le Gao, Tian Yang, Ziru Xue, Chak Kwan Dickson Chan
Life.2023; 13(2): 337. CrossRef - Abdominal fat and muscle distributions in different stages of colorectal cancer
Jun Han, Xinyang Liu, Min Tang, Fan Yang, Zuoyou Ding, Guohao Wu
BMC Cancer.2023;[Epub] CrossRef - Arterial stiffness is associated with high-risk colorectal adenomas and serrated lesions: A cross-sectional study in a Taiwanese population
Hung-Yu Chen, Wen-Huang Lee, Hung-Lung Hsu, Yu-Tsung Chou, Fei-Lin Su, I-Hsuan Wu, Ting-Hsing Chao
Journal of Cardiology.2022; 80(2): 139. CrossRef - Relationship between BMI, CT-derived body composition and colorectal neoplasia in a bowel screening population
Domenic G. Di Rollo, Josh McGovern, Christopher Morton, Gillian Miller, Ross Dolan, Paul G. Horgan, Donald C. McMillan, David Mansouri
Scottish Medical Journal.2022; 67(3): 93. CrossRef - Review article: obesity and colorectal cancer
Marc Bardou, Alexia Rouland, Myriam Martel, Romaric Loffroy, Alan N. Barkun, Nicolas Chapelle
Alimentary Pharmacology & Therapeutics.2022; 56(3): 407. CrossRef - The Association of Waist Circumference with the Prevalence and Survival of Digestive Tract Cancer in US Adults: A Population Study Based on Machine Learning Methods
Xingyu Jiang, Qi Liang, Huanhuan Xu, Shouyong Gu, Lingxiang Liu, Jincheng Wang
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef - Obesity Is Not an Independent Predictor of Necrotizing Soft Tissue Infection Outcomes
Hannah Zhao-Fleming, Mhd Hasan Almekdash, Elizabeth Cook, Armand Northcut, Diana Mitchell, Kendra Rumbaugh, Sharmila Dissanaike
Surgical Infections.2021; 22(2): 187. CrossRef - Optimization of the surveillance strategy in patients with colorectal adenomas: A combination of clinical parameters and index colonoscopy findings
Chan Hyuk Park, Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
Journal of Gastroenterology and Hepatology.2021; 36(4): 974. CrossRef - Obesity, sleep apnea, and cancer
Isaac Almendros, Miguel A. Martinez-Garcia, Ramon Farré, David Gozal
International Journal of Obesity.2020; 44(8): 1653. CrossRef - Opportunistic use of radiological measures of visceral adiposity for assessment of risk of colorectal adenoma
Zi Qin Ng, Ruwan Wijesuriya, Philip Misur, Jih Huei Tan, Kyaw Soe Moe, Mary Theophilus
ANZ Journal of Surgery.2020; 90(11): 2298. CrossRef - Changes in Abdominal Obesity Affect the Risk of Metachronous Advanced Colorectal Neoplasia Development after Polypectomy
Yoon Suk Jung, Nam Hee Kim, Jung Ho Park, Dong Il Park, Chong Il Sohn
Yonsei Medical Journal.2020; 61(7): 579. CrossRef
- Change in abdominal obesity after colon cancer surgery – effects of left-sided and right-sided colonic resection
- 40,097 View
- 182 Download
- 15 Web of Science
- 15 Crossref
- Colorectal neoplasia
- Endoscopic features of gastrointestinal stromal tumor in the small intestine
- Yutaro Ihara, Takehiro Torisu, Tomohiko Moriyama, Junji Umeno, Atsushi Hirano, Yasuharu Okamoto, Yoshifumi Hori, Hidetaka Yamamoto, Takanari Kitazono, Motohiro Esaki
- Intest Res 2019;17(3):398-403. Published online July 25, 2019
- DOI: https://doi.org/10.5217/ir.2018.00161
-
Abstract
PDFPubReaderePub
- Background/Aims
Gastrointestinal stromal tumor (GIST) is one of the most common types of submucosal tumors (SMTs). Because of GIST’s malignant potential, it is crucial to differentiate it from other SMTs. The present study aimed to identify characteristic endoscopic findings of GISTs in the small intestine.
Methods
We reviewed the clinicopathological and endoscopic findings of 38 patients with endoscopically or surgically resected SMTs in the small intestine. SMTs were classified into GIST and non-GIST groups, and clinicopathological and endoscopic findings were compared between the 2 groups.
Results
Fifteen patients had GIST and 23 patients had other types of SMTs in the small intestine. Comparison of the endoscopic findings between the 2 groups revealed that dilated vessels in the surrounding mucosa were significantly more in number in the GIST group than in the non-GIST group (P<0.05). However, there were no other differences in endoscopic findings between the 2 groups. Among patients with GISTs, the presence of dilated vessels in the surrounding mucosa was not associated with bleeding risk, tumor size, or metastasis rate at diagnosis.
Conclusions
Dilated vessels in the surrounding mucosa, identified during balloon-assisted endoscopy, may be a diagnostic indicator for GIST in the small intestine. However, its clinical significance should be further analyzed. -
Citations
Citations to this article as recorded by- Multiple Small Bowel Gastrointestinal Stromal Tumors Associated with Neurofibromatosis Type 1 that Were Not Detected by Endoscopy: A Case Report
Satomi Saito, Teppei Omori, Shun Murasugi, Maria Yonezawa, Yukiko Takayama, Takeshi Ohki, Hiromi Onizuka, Yoji Nagashima, Katsutoshi Tokushige
Case Reports in Gastroenterology.2023; 17(1): 167. CrossRef - Convolutional neural network‐based object detection model to identify gastrointestinal stromal tumors in endoscopic ultrasound images
Chang Kyo Oh, Taewan Kim, Yu Kyung Cho, Dae Young Cheung, Bo‐In Lee, Young‐Seok Cho, Jin Il Kim, Myung‐Gyu Choi, Han Hee Lee, Seungchul Lee
Journal of Gastroenterology and Hepatology.2021; 36(12): 3387. CrossRef - Small Bowel Malignancies in Patients Undergoing Capsule Endoscopy for Iron Deficiency Anemia
Su Hwan Kim, Ji Won Kim
Diagnostics.2021; 12(1): 91. CrossRef
- Multiple Small Bowel Gastrointestinal Stromal Tumors Associated with Neurofibromatosis Type 1 that Were Not Detected by Endoscopy: A Case Report
- 7,768 View
- 119 Download
- 5 Web of Science
- 3 Crossref
- Inflammatory bowel diseases
- Quantitative histology-based classification system for assessment of the intestinal mucosal histological changes in patients with celiac disease
- Prasenjit Das, Gaurav PS Gahlot, Alka Singh, Vandana Baloda, Ramakant Rawat, Anil K Verma, Gaurav Khanna, Maitrayee Roy, Archana George, Ashok Singh, Aasma Nalwa, Prashant Ramteke, Rajni Yadav, Vineet Ahuja, Vishnubhatla Sreenivas, Siddhartha Datta Gupta, Govind K Makharia
- Intest Res 2019;17(3):387-397. Published online April 22, 2019
- DOI: https://doi.org/10.5217/ir.2018.00167
-
Abstract
PDFPubReaderePub
- Background/Aims
The existing histological classifications for the interpretation of small intestinal biopsies are based on qualitative parameters with high intraobserver and interobserver variations. We have developed and propose a quantitative histological classification system for the assessment of intestinal mucosal biopsies.
Methods
We performed a computer-assisted quantitative histological assessment of digital images of duodenal biopsies from 137 controls and 124 patients with celiac disease (CeD) (derivation cohort). From the receiver-operating curve analysis, followed by multivariate and logistic regression analyses, we identified parameters for differentiating control biopsies from those of the patients with CeD. We repeated the quantitative histological analysis in a validation cohort (105 controls and 120 patients with CeD). On the basis of the results, we propose a quantitative histological classification system. The new classification was compared with the existing histological classifications for interobserver and intraobserver agreements by a group of qualified pathologists.
Results
Among the histological parameters, intraepithelial lymphocyte count of ≥25/100 epithelial cells, adjusted villous height fold change of ≤0.7, and crypt depth-to-villous height ratio of ≥0.5 showed good discriminative power between the mucosal biopsies from the patients with CeD and those from the controls, with 90.3% sensitivity, 93.5% specificity, and 96.2% area under the curve. Among the existing histological classifications, our quantitative histological classification showed the highest intraobserver (69.7%–85.03%) and interobserver (24.6%–71.5%) agreements.
Conclusions
Quantitative assessment increases the reliability of the histological assessment of mucosal biopsies in patients with CeD. Such a classification system may be used for clinical trials in patients with CeD. (Intest Res, Published online) -
Citations
Citations to this article as recorded by- Celiac Disease Deep Learning Image Classification Using Convolutional Neural Networks
Joaquim Carreras
Journal of Imaging.2024; 10(8): 200. CrossRef - CD, or not CD, that is the question: a digital interobserver agreement study in coeliac disease
James Denholm, Benjamin A Schreiber, Florian Jaeckle, Mike N Wicks, Emyr W Benbow, Tim S Bracey, James Y H Chan, Lorant Farkas, Eve Fryer, Kishore Gopalakrishnan, Caroline A Hughes, Kathryn J Kirkwood, Gerald Langman, Betania Mahler-Araujo, Raymond F T Mc
BMJ Open Gastroenterology.2024; 11(1): e001252. CrossRef - Role of Serology, Dietary Assessment, and Fecal Gluten Immunogenic Peptides for Predicting Histologic Recovery in Children with Celiac Disease
Keerthivasan Seetharaman, Sadhna Bhasin Lal, Kaushal Kishor Prasad, Yashwant Kumar, Alka Bhatia, Sunita Malhotra
Digestive Diseases and Sciences.2023; 68(2): 529. CrossRef - Usefulness of a double immunofluorescence technique for detection of intestinal tTG-IgA deposits in diabetic and non-diabetic children with celiac disease
Raghav Lal, Ranjeet Bhardwaj, Ranjana Walker Minz, Kaushal Kishore Prasad, Sadhna Lal, Devi Dayal, Yashwant Kumar
Pediatrics & Neonatology.2023; 64(4): 388. CrossRef - The global burden of coeliac disease: opportunities and challenges
Govind K. Makharia, Prashant Singh, Carlo Catassi, David S. Sanders, Daniel Leffler, Raja Affendi Raja Ali, Julio C. Bai
Nature Reviews Gastroenterology & Hepatology.2022; 19(5): 313. CrossRef - Gluten Induces Subtle Histological Changes in Duodenal Mucosa of Patients with Non-Coeliac Gluten Sensitivity: A Multicentre Study
Kamran Rostami, Arzu Ensari, Michael N. Marsh, Amitabh Srivastava, Vincenzo Villanacci, Antonio Carroccio, Hamid Asadzadeh Aghdaei, Julio C. Bai, Gabrio Bassotti, Gabriel Becheanu, Phoenix Bell, Camillo Di Bella, Anna Maria Bozzola, Moris Cadei, Giovanni
Nutrients.2022; 14(12): 2487. CrossRef - The Role of Nerve Fibers in the Tumor Immune Microenvironment of Solid Tumors
Sharia Hernandez, Alejandra G. Serrano, Luisa M. Solis Soto
Advanced Biology.2022;[Epub] CrossRef - Case Report: Morphologic and Functional Characteristics of Intestinal Mucosa in a Child With Short Bowel Syndrome After Treatment With Teduglutide: Evidence in Favor of GLP-2 Analog Safety
Enrico Costantino Falco, Antonella Lezo, Pierluigi Calvo, Caterina Rigazio, Anna Opramolla, Ludovica Verdun, Giovanna Cenacchi, Marianna Pellegrini, Marco Spada, Gabriella Canavese
Frontiers in Nutrition.2022;[Epub] CrossRef - Quantitative histology as a diagnostic tool for celiac disease in children and adolescents
Mateus M. Vargas, Ricardo Artigiani Neto, Vera L. Sdepanian
Annals of Diagnostic Pathology.2022; 61: 152031. CrossRef - Best practices of handling, processing, and interpretation of small intestinal biopsies for the diagnosis and management of celiac disease: A joint consensus of Indian association of pathologists and microbiologists and Indian society of gastroenterology
Prasenjit Das, Kim Vaiphei, AnjaliD Amarapurkar, Puja Sakhuja, Ritambhra Nada, RoopaRachel Paulose, Rachana Chaturvedi, Anuradha Sekaran, Usha Kini, Archana Rastogi, Niraj Kumari, Anna Pulimood, Mala Banerjee, Prateek Kinra, Lavleen Singh, AmarenderSingh
Indian Journal of Pathology and Microbiology.2021; 64(5): 8. CrossRef - Artificial intelligence in small intestinal diseases: Application and prospects
Yu Yang, Yu-Xuan Li, Ren-Qi Yao, Xiao-Hui Du, Chao Ren
World Journal of Gastroenterology.2021; 27(25): 3734. CrossRef - Opportunities and challenges in the management of celiac disease in Asia
Ashish Agarwal, Ashish Chauhan, Vineet Ahuja, Govind K Makharia
JGH Open.2020; 4(5): 795. CrossRef - Digital histology in celiac disease: A practice changer
Daniel Vasile Balaban, Mariana Jinga
Artificial Intelligence in Gastroenterology.2020; 1(1): 1. CrossRef - Digital histology in celiac disease: A practice changer
Daniel Vasile Balaban, Mariana Jinga
Artificial Intelligence in Gastroenterology.2020; 1(1): 1. CrossRef
- Celiac Disease Deep Learning Image Classification Using Convolutional Neural Networks
- 7,817 View
- 181 Download
- 13 Web of Science
- 14 Crossref
- Inflammatory bowel diseases
- Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
- Toshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, Souken Sai, Yukinori Sameshima, Shiro Nakamura, Atsuo Maemoto, Masahiro Nii, Barbara A Sullivan, Robert A. Gasser Jr, Yasuo Suzuki
- Intest Res 2019;17(3):375-386. Published online February 12, 2019
- DOI: https://doi.org/10.5217/ir.2018.00141
-
Abstract
PDFPubReaderePub
- Background/Aims
Inhibition of α4β7 integrin has been shown to be effective for induction and maintenance therapy in patients with ulcerative colitis (UC). We investigated the effects of varying doses of the α4β7 inhibitor abrilumab in Japanese patients with moderate-to-severe UC despite conventional treatments.
Methods
In this randomized, double-blind, placebocontrolled study, 45 UC patients were randomized to abrilumab 21 mg (n=11), 70 mg (n=12), 210 mg (n=9), or placebo (n=13) via subcutaneous (SC) injection for 12 weeks. The double-blind period was followed by a 36-week open-label period, in which all patients received abrilumab 210 mg SC every 12 weeks, and a 28-week safety follow-up period. The primary efficacy variable was clinical remission at week 8 (total Mayo score ≤2 points with no individual subscore >1 point).
Results
Clinical remission at week 8 was 4 out of 31 (12.9%) overall in the abrilumab groups versus 0 out of 13 in the placebo group (abrilumab 21 mg, 1/10 [10.0%]; 70 mg, 2/12 [16.7%]; 210 mg, 1/9 [11.1%]). In both the double-blind and open-label periods, fewer patients in the abrilumab groups experienced ≥1 adverse event compared with those in the placebo group. There were no cases of progressive multifocal leukoencephalopathy and no deaths.
Conclusions
Abrilumab 70 mg and 210 mg yielded numerically better results in terms of clinical remission rate at Week 8 than placebo, with the 210 mg dose showing more consistent treatment effects. Abrilumab was well tolerated in Japanese patients with UC. -
Citations
Citations to this article as recorded by- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis
Lorenzo Vittorio Rindi, Drieda Zaçe, Neva Braccialarghe, Barbara Massa, Virginia Barchi, Roberta Iannazzo, Ilenia Fato, Francesco De Maria, Dimitra Kontogiannis, Vincenzo Malagnino, Loredana Sarmati, Marco Iannetta
Drug Safety.2024; 47(4): 333. CrossRef - Targeting integrin pathways: mechanisms and advances in therapy
Xiaocong Pang, Xu He, Zhiwei Qiu, Hanxu Zhang, Ran Xie, Zhiyan Liu, Yanlun Gu, Nan Zhao, Qian Xiang, Yimin Cui
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef - Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials
Laura Neurath, Ferdinando D’Amico, Silvio Danese
Expert Opinion on Emerging Drugs.2023; 28(1): 27. CrossRef - Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
Elisabetta Bretto, Davide Giuseppe Ribaldone, Gian Paolo Caviglia, Giorgio Maria Saracco, Elisabetta Bugianesi, Simone Frara
Biomedicines.2023; 11(8): 2249. CrossRef - Integrin signaling in cancer: bidirectional mechanisms and therapeutic opportunities
Siyi Li, Chibuzo Sampson, Changhao Liu, Hai-long Piao, Hong-Xu Liu
Cell Communication and Signaling.2023;[Epub] CrossRef - Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics
Quan Lu, Mei-feng Yang, Yu-jie Liang, Jing Xu, Hao-ming Xu, Yu-qiang Nie, Li-sheng Wang, Jun Yao, De-feng Li
Journal of Inflammation Research.2022; Volume 15: 1825. CrossRef - Factors predicting clinical and endoscopic remission with placebo therapy in East Asian patients with ulcerative colitis: a systematic review and meta-analysis
Jian Zeng, Zhong Wang, Xiao-Jun Yang
European Journal of Clinical Pharmacology.2022; 78(7): 1069. CrossRef - Tackling Inflammatory Bowel Diseases: Targeting Proinflammatory Cytokines and Lymphocyte Homing
Yijie Song, Man Yuan, Yu Xu, Hongxi Xu
Pharmaceuticals.2022; 15(9): 1080. CrossRef - Targeting Immune Cell Trafficking – Insights From Research Models and Implications for Future IBD Therapy
Maximilian Wiendl, Emily Becker, Tanja M. Müller, Caroline J. Voskens, Markus F. Neurath, Sebastian Zundler
Frontiers in Immunology.2021;[Epub] CrossRef - Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives
John Gubatan, Kian Keyashian, Samuel JS Rubin, Jenny Wang, Cyrus Buckman, Sidhartha Sinha
Clinical and Experimental Gastroenterology.2021; Volume 14: 333. CrossRef - Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents
Virginia Solitano, Tommaso Lorenzo Parigi, Elisa Ragaini, Silvio Danese
Expert Opinion on Investigational Drugs.2021; 30(10): 1037. CrossRef - Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis
Taku Kobayashi, Hiroaki Ito, Toshifumi Ashida, Tadashi Yokoyama, Masakazu Nagahori, Tomoki Inaba, Mitsuhiro Shikamura, Takayoshi Yamaguchi, Tetsuharu Hori, Philippe Pinton, Mamoru Watanabe, Toshifumi Hibi
Intestinal Research.2021; 19(4): 448. CrossRef - Emerging therapeutic options in inflammatory bowel disease
Jesus K Yamamoto-Furusho, Norma N Parra-Holguín
World Journal of Gastroenterology.2021; 27(48): 8242. CrossRef - Subcutaneous integrin inhibitors may provide more treatment options for patients with moderate-to-severe ulcerative colitis
Hyuk Yoon
Intestinal Research.2019; 17(3): 283. CrossRef
- Drug-Induced Progressive Multifocal Leukoencephalopathy (PML): A Systematic Review and Meta-Analysis
- 7,593 View
- 204 Download
- 15 Web of Science
- 14 Crossref
- Inflammatory bowel diseases
- Real-time data monitoring for ulcerative colitis: patient perception and qualitative analysis
- Alissa Walsh, Lawrence Matini, Christopher Hinds, Vanashree Sexton, Oliver Brain, Satish Keshav, John Geddes, Guy Goodwin, Gary Collins, Simon Travis, Michele Peters
- Intest Res 2019;17(3):365-374. Published online May 31, 2019
- DOI: https://doi.org/10.5217/ir.2018.00173
-
Abstract
PDFPubReaderePub
- Background/Aims
TrueColours ulcerative colitis (TCUC) is a comprehensive web-based program that functions through email, providing direct links to questionnaires. Several similar programs are available, however patient perspectives are unexplored.
Methods
A pilot study was conducted to determine feasibility, usability and patient perceptions of real-time data collection (daily symptoms, fortnightly quality of life, 3 monthly outcomes). TCUC was adapted from a web-based program for patients with relapsing-remitting bipolar disorder, using validated UC indices. A semi-structured interview was developed and audio-recorded face-to-face interviews were conducted after 6 months of interaction with TCUC. Transcripts were coded in NVivo11, a qualitative data analysis software package. An inductive approach and thematic analysis was conducted.
Results
TCUC was piloted in 66 patients for 6 months. Qualitative analysis currently defies statistical appraisal beyond “data saturation,” even if it has more influence on clinical practice than quantitative data. A total of 28 face-to-face interviews were conducted. Six core themes emerged: awareness, control, decision-making, reassurance, communication and burden of treatment. There was a transcending overarching theme of patient empowerment, which cut across all aspects of the TCUC experience.
Conclusions
Patient perception of the impact of real-time data collection was extremely positive. Patients felt empowered as a product of the self-monitoring format of TCUC, which may be a way of improving self-management of UC whilst also decreasing the burden on the individual and healthcare services. -
Citations
Citations to this article as recorded by- Investigating Patient Perspectives on Using eHealth Technologies for the Self-Management of Inflammatory Bowel Disease: Mixed Methods Study
Sander Hermsen, Danielle Tump, Eva Wentink, Marjolijn Duijvestein
Journal of Medical Internet Research.2024; 26: e53512. CrossRef - The body as an obstacle and the “other”. How patients with chronic inflammatory bowel diseases view their body, self and the good life
Anke Erdmann, Christoph Rehmann-Sutter, Florian Schrinner, Claudia Bozzaro
BMC Medical Ethics.2024;[Epub] CrossRef - Development of the Escalation of Therapy or Intervention (ETI) Calculator for Patients with Ulcerative Colitis Using ePROMs
Lawrence Matini, Thomas P Chapman, Ramona Kantschuster, Jean Wilson, Adib Tarafdar, Moheez Hussain, Kaiyang Song, Daniel M Simadibrata, Pavetha Seeva, Lydia White, Jessica Slater, Andrey Kormilitzin, Gary Collins, Simon P L Travis, Alissa Walsh
Journal of Crohn's and Colitis.2023; 17(11): 1744. CrossRef - Deep learning model for distinguishing Mayo endoscopic subscore 0 and 1 in patients with ulcerative colitis
Ji Eun Kim, Yoon Ho Choi, Yeong Chan Lee, Gyeol Seong, Joo Hye Song, Tae Jun Kim, Eun Ran Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim, Soo-Yong Shin
Scientific Reports.2023;[Epub] CrossRef - Patient-reported Outcomes: the ICHOM Standard Set for Inflammatory Bowel Disease in Real-life Practice Helps Quantify Deficits in Current Care
Darren Wong, Lawrence Matini, Andrey Kormilitzin, Ramona Kantschuster, Daniel Martin Simadibrata, Sara Lyden, Jean Wilson, Oliver A Brain, Rebecca Palmer, Tim Ambrose, Jack Satsangi, Matthew South, John Geddes, Keith Bodger, Simon P L Travis, Alissa Walsh
Journal of Crohn's and Colitis.2022; 16(12): 1874. CrossRef - Analysis of the Current Situation of Teaching and Learning of Ideological and Political Theory Courses by Deep Learning
Jin Chao, Yijiang Zhang, Arpit Bhardwaj
Computational Intelligence and Neuroscience.2022; 2022: 1. CrossRef - Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians
David T Rubin, Ailsa Hart, Remo Panaccione, Alessandro Armuzzi, Ulla Suvanto, J Jasper Deuring, John Woolcott, Joseph C Cappelleri, Kathy Steinberg, Laura Wingate, Stefan Schreiber
Inflammatory Bowel Diseases.2021; 27(7): 1096. CrossRef - Telehealth and mobile health interventions in adults with inflammatory bowel disease: A mixed‐methods systematic review
Suja P. Davis, Megan Suzanne Hardin Ross, Reuben Adatorwovor, Holly Wei
Research in Nursing & Health.2021; 44(1): 155. CrossRef - COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
Richard H. Hunt, James E. East, Angel Lanas, Peter Malfertheiner, Jack Satsangi, Carmelo Scarpignato, Gwilym J. Webb
Digestive Diseases.2021; 39(2): 119. CrossRef - The True Colours Remote Symptom Monitoring System: A Decade of Evolution
Sarah M Goodday, Lauren Atkinson, Guy Goodwin, Kate Saunders, Matthew South, Clare Mackay, Mike Denis, Chris Hinds, Mary-Jane Attenburrow, Jim Davies, James Welch, William Stevens, Karen Mansfield, Juulia Suvilehto, John Geddes
Journal of Medical Internet Research.2020; 22(1): e15188. CrossRef - Developments and challenges of e-health strategies for people with inflammatory bowel disease
Pearl Avery
British Journal of Healthcare Management.2020; 26(3): 73. CrossRef - Pathogenesis and clinical perspectives of extraintestinal manifestations in inflammatory bowel diseases
Jung Min Kim, Jae Hee Cheon
Intestinal Research.2020; 18(3): 249. CrossRef - The UK IBD Registry COVID-19 Risk Tool; Patient Generated Data Can Improve the Hospital Record
Nicholas A. Kennedy, Naila Arebi, Keith Bodger, Vida Cairnes, R. Fraser Cummings, Liz Dobson, Stephen Grainger, Paul Harrow, A. Barney Hawthorne, Gareth-Rhys Jones, Alexandra Kent, Shaji Sebastian, Christian Selinger, Gareth J. Walker, Lisa Younge, Stuart
SSRN Electronic Journal .2020;[Epub] CrossRef
- Investigating Patient Perspectives on Using eHealth Technologies for the Self-Management of Inflammatory Bowel Disease: Mixed Methods Study
- 64,082 View
- 139 Download
- 13 Web of Science
- 13 Crossref
- Inflammatory bowel diseases
- Risk of surgery in patients with stricturing type of Crohn’s disease at the initial diagnosis: a single center experience
- Yuji Maehata, Yutaka Nagata, Tomohiko Moriyama, Yuichi Matsuno, Atsushi Hirano, Junji Umeno, Takehiro Torisu, Tatsuya Manabe, Takanari Kitazono, Motohiro Esaki
- Intest Res 2019;17(3):357-364. Published online February 21, 2019
- DOI: https://doi.org/10.5217/ir.2018.00107
-
Abstract
PDFPubReaderePub
- Background/Aims
It remains uncertain which patients with stricturing-type Crohn’s disease (CD) require early small bowel surgery after the initial diagnosis. We aimed to clarify clinical characteristics associated with the intervention in such condition of CD.
Methods
We retrospectively evaluated the clinical course of 53 patients with CD and small bowel strictures who were initially treated with medications after the initial diagnosis. We investigated possible associations between small bowel surgery and the following: clinical factors and radiologic findings at initial diagnosis and the types of medications administered during follow-up.
Results
Twenty-eight patients (53%) required small bowel resection during a median follow-up period of 5.0 years (range, 0.5–14.3 years). The cumulative incidence rates of small bowel surgery at 2, 5, and 10 years were 26.4%, 41.0%, and 63.2%, respectively. Univariate analysis indicated that obstructive symptoms (P=0.036), long-segment stricture (P<0.0001), and prestenotic dilation (P<0.0001) on radiography were associated with small bowel surgery, and immunomodulatory (P=0.037) and biological therapy (P=0.008) were significant factors during follow-up. Multivariate analysis revealed that long-segment stricture (hazard ratio [HR], 4.25; 95% confidence interval [CI], 1.78–10.53; P=0.001) and prestenotic dilation (HR, 3.41; 95% CI, 1.24–9.62; P=0.018) on radiography showed a positive correlation with small bowel surgery, and biological therapy (HR, 0.40; 95% CI, 0.15–0.99; P=0.048) showed a negative correlation.
Conclusions
CD patients with long-segment stricture and prestenotic dilation on radiography seem to be at a higher risk of needing small bowel surgery. For such patients, early surgical intervention might be appropriate, even at initial diagnosis. -
Citations
Citations to this article as recorded by- Comprehensive review and update of stricturing Crohn’s disease
Alexander T. Elford, Zaid Ardalan, Paul Simkin, Britt Christensen
Indian Journal of Gastroenterology.2024; 43(1): 64. CrossRef - A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice
Dominik Bettenworth, Mark E. Baker, Joel G. Fletcher, Vipul Jairath, Cathy Lu, Willem Bemelman, Geert d’Haens, Andre d’Hoore, Axel Dignass, Iris Dotan, Roger Feakins, Phillip Fleshner, Christina Ha, Gaylyn Henderson, Ruishen Lyu, Julian Panes, Gerhard Rog
Nature Reviews Gastroenterology & Hepatology.2024; 21(8): 572. CrossRef - Reliability of MR Enterography Features for Describing Fibrostenosing Crohn Disease
Florian Rieder, Mark E. Baker, David H. Bruining, Jeff L. Fidler, Eric C. Ehman, Shannon P. Sheedy, Jay P. Heiken, Justin M. Ream, David R. Holmes, Akitoshi Inoue, Payam Mohammadinejad, Yong S. Lee, Stuart A. Taylor, Jaap Stoker, Guangyong Zou, Zhongya Wa
Radiology.2024;[Epub] CrossRef - Reliability of CT Enterography for Describing Fibrostenosing Crohn Disease
Florian Rieder, Christopher Ma, Jurij Hanzel, Joel G. Fletcher, Mark E. Baker, Zhongya Wang, Leonardo Guizzetti, Lisa M. Shackelton, Julie Rémillard, Mihir Patel, Jiafei Niu, Ronald Ottichilo, Cynthia S. Santillan, Nunzia Capozzi, Stuart A. Taylor, David
Radiology.2024;[Epub] CrossRef - Use of oral diet and nutrition support in management of stricturing and fistulizing Crohn's disease
Kush Fansiwala, Neha D. Shah, Kelly A. McNulty, Mary R. Kwaan, Berkeley N. Limketkai
Nutrition in Clinical Practice.2023; 38(6): 1282. CrossRef - Sarcopenia hinders the decline in disease activity after surgery for people with Crohn's disease: Preliminary results
Asuka Yasueda, Yuki Sekido, Takashi Takeda, Takayuki Ogino, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Yuichiro Doki, Hidetoshi Eguchi, Tsunekazu Mizushima
Nutrition.2022; 94: 111526. CrossRef - Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review
Julien D Schulberg, Emily K Wright, Bronte A Holt, Helen E Wilding, Amy L Hamilton, Alyson L Ross, Michael A Kamm
Journal of Gastroenterology and Hepatology.2021; 36(2): 344. CrossRef - Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Yoon Suk Jung, Minkyung Han, Sohee Park, Jae Hee Cheon
Gut and Liver.2021; 15(1): 92. CrossRef - Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease
Muaad Abdulla, Thean Soon Chew
Current Opinion in Gastroenterology.2021; 37(3): 275. CrossRef - Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn’s disease
Sudheer K. Vuyyuru, Bhaskar Kante, Peeyush Kumar, Pabitra Sahu, Saurabh Kedia, Mukesh Kumar Ranjan, Raju Sharma, Rajesh Panwar, Govind Makharia, Vineet Ahuja
Scientific Reports.2021;[Epub] CrossRef - Inpatient Management of Inflammatory Bowel Disease-Related Complications
Manreet Kaur, Robin L. Dalal, Seth Shaffer, David A. Schwartz, David T. Rubin
Clinical Gastroenterology and Hepatology.2020; 18(6): 1346. CrossRef - Surgical treatment of intestinal stricture in inflammatory bowel disease
Helen M. Mohan, John C. Coffey
Journal of Digestive Diseases.2020; 21(6): 355. CrossRef
- Comprehensive review and update of stricturing Crohn’s disease
- 7,094 View
- 182 Download
- 12 Web of Science
- 12 Crossref
- Inflammatory bowel diseases
- Adherence to Asacol once daily versus divided regimen for maintenance therapy in ulcerative colitis: a prospective, multicenter, randomized study
- Soo-Kyung Park, Sang Hyun Park, Chang Soo Eun, Geom Seog Seo, Jong Pil Im, Tae Oh Kim, Dong-Il Park
- Intest Res 2019;17(3):349-356. Published online February 8, 2019
- DOI: https://doi.org/10.5217/ir.2018.00064
-
Abstract
PDFPubReaderePub
- Background/Aims
A once-daily (OD) regimen of 5-aminosalicylic acid (5-ASA) was easier to comply with than a divided daily (DD) regimen, and that treatment efficacy for ulcerative colitis (UC) was not affected by the dosing regimen. This study evaluated treatment adherence of OD and DD dosing in the Korean UC patients.
Methods
This study was a prospective, multicenter, randomized trial. UC patients were enrolled who have been in remission for more than 3 months. Patients were randomly assigned to the OD or DD group in a 1:1 ratio. The primary endpoint was adherence rate measured by tablet counts and self-reported adherence rate at 3, 6, 9, and 12 months. The relapse rate was measured at 1 year.
Results
Data from the 180 patients who were randomized were analyzed. Both self-reported adherence rate and adherence rate measured by tablet counts were not different at every points, including 1 year. The patients’ satisfaction of the OD group was higher than that of the DD group (P<0.001). At 1 year, 91.2% and 95.5% of patients in the OD group and DD group had maintained clinical remission, respectively (P=0.37).
Conclusions
The adherence rates were not different between the OD group and DD group. The patients’ satisfaction was higher in the OD group than in the DD group. 5-ASA OD dosing might have the same effect as DD for the maintenance of UC remission. -
Citations
Citations to this article as recorded by- Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
Obreniokibo Amiesimaka, Kristina Aluzaite, Rhiannon Braund, Michael Schultz
Patient Preference and Adherence.2024; Volume 18: 905. CrossRef - Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef - Researching Interventions to Improve Medication Adherence in Ulcerative Colitis Patients
Mila Palma Pacheco, Flora Maria Lorenzo Fortes, Raquel Rocha dos Santos, Genoile Oliveira Santana Silva
Journal of Coloproctology.2021; 41(01): 096. CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs
Axel Dignass, John Waller, Joseph C. Cappelleri, Irene Modesto, Agnes Kisser, Lena Dietz, Marco DiBonaventura, Robert Wood, Melanie May, Berit Libutzki, Danielle Bargo
Journal of Medical Economics.2020; 23(4): 415. CrossRef - Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis
Alistair Murray, Tran M Nguyen, Claire E Parker, Brian G Feagan, John K MacDonald
Cochrane Database of Systematic Reviews.2020;[Epub] CrossRef
- Improving Medication Adherence Levels in Inflammatory Bowel Disease (IBD) Patients: A Narrative Evidence-Based Review
- 8,379 View
- 192 Download
- 6 Web of Science
- 6 Crossref
- Inflammatory bowel diseases
- Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
- Sadik Saman, Martin Goetz, Judith Wendler, Nisar P. Malek, Jan Wehkamp, Thomas Klag
- Intest Res 2019;17(3):340-348. Published online May 31, 2019
- DOI: https://doi.org/10.5217/ir.2019.00012
-
Abstract
PDFPubReaderePub
- Background/Aims
Ustekinumab is effective in active Crohn’s disease. In a retrospective study we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average “real world” patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes.
Methods
Forty-one patients with mild to severe active Crohn’s disease were treated with ustekinumab (intravenous 6 mg per kg/body weight) followed by subcutaneous ustekinumab (90 mg) at week 8. Depending on the clinical response maintenance therapy was chosen every 8 or 12 weeks. Clinical response was defined by Crohn’s Disease Activity Index (CDAI) decline, decline of stool frequency or clinical improvement. Inclusion criteria for approval studies were assessed.
Results
The 58.5% (24/41) showed clinical response to ustekinumab. The 58.3% of this group (14/24) achieved clinical remission. Clinical response correlated significantly with drop of stool frequency and improvement of CDAI score. The 39 out of 41 patients had no side effects and we observed no serious infections. About a third of our patients would not have met ustekinumab approval study criteria. However, patients who did not meet study criteria showed clinical improvement numerically in the same range compared to patients who would have qualified for approval studies.
Conclusions
Ustekinumab is effective, safe and well tolerated in a highly therapy refractory patient cohort. Even though a reasonable number of patients did not meet ustekinumab approval study criteria, approval study results seem to be representative to the overall patient cohort. -
Citations
Citations to this article as recorded by- Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis
Yaqing Bai, Yinghao Sun, Qi He, Xiaoyin Bai, Hong Yang
European Journal of Gastroenterology & Hepatology.2024; 36(4): 359. CrossRef - Long-term real-world data of ustekinumab in Crohn’s disease: the Stockholm ustekinumab study
Francesca Bello, Samer Muhsen, Haider Sabhan, Alexandra Borin, Fredrik Johansson, Charlotte Höög, Ole Forsberg, Christina Wennerström, Charlotte Söderman, Mikael Lördal, Sven Almer
Therapeutic Advances in Gastroenterology.2024;[Epub] CrossRef - Effectiveness and Safety of Ustekinumab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Sailish Honap, Susanna Meade, Hajir Ibraheim, Peter M. Irving, Michael P. Jones, Mark A. Samaan
Digestive Diseases and Sciences.2022; 67(3): 1018. CrossRef - Systematic review with meta‐analysis: loss of response and requirement of ustekinumab dose escalation in inflammatory bowel diseases
Hongsheng Yang, Bingyang Li, Qin Guo, Jian Tang, Bo Peng, Ni Ding, Miao Li, Qingfang Yang, Zicheng Huang, Na Diao, Xia Zhu, Jun Deng, Huili Guo, Pinjin Hu, Kang Chao, Xiang Gao
Alimentary Pharmacology & Therapeutics.2022; 55(7): 764. CrossRef - Clinically reversible ustekinumab-induced encephalopathy: case report and review of the literature
Jordi Sarto, Berta Caballol, Joan Berenguer, Iban Aldecoa, Álvaro Carbayo, Daniel Santana, Ivan Archilla, Carles Gaig, Francesc Graus, Julián Panés, Albert Saiz
Therapeutic Advances in Neurological Disorders.2022;[Epub] CrossRef - Safety and Efficacy of Ustekinumab in the Treatment of Crohn Disease: A Systematic Review and Meta-analysis
Mohammed Assem Khorshid, Ahmed Cordie, Sherief Abd-Elsalam
Journal of Coloproctology.2022; 42(02): 178. CrossRef - Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies
Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Journal of Clinical Medicine.2022; 11(14): 4202. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn’s disease (PROSE): a 16-week follow-up
Anders Forss, Mark Clements, Pär Myrelid, Hans Strid, Charlotte Söderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olén, Jonas F. Ludvigsson, Jonas Halfvarson
Scandinavian Journal of Gastroenterology.2021; 56(6): 680. CrossRef - Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis
Seungwon Yang, Siyoung Yang, Young Kwon Jo, Seungyeon Kim, Min Jung Chang, Junjeong Choi, Jae Hee Cheon, Yun Mi Yu
Therapeutic Advances in Chronic Disease.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Eficacia y seguridad de ustekinumab en la práctica clínica real. Estudio multicéntrico retrospectivo. Cohorte ARAINF
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino
Gastroenterología y Hepatología.2020; 43(3): 126. CrossRef - Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies
Fabio Salvatore Macaluso, Marcello Maida, Marco Ventimiglia, Mario Cottone, Ambrogio Orlando
Expert Opinion on Biological Therapy.2020; 20(2): 193. CrossRef - Efficacy and safety of ustekinumab in real clinical practice. Retrospective multicentre study. ARAINF cohort
Diego Casas Deza, Santiago García López, Miguel Lafuente Blasco, Raquel Vicente Lidón, Juan Nerín de la Puerta, Elena Peña Gonzalez, Yolanda Ber Nieto, Mara Charro Calvillo, María José Alcalá Escriche, Fernando Gomollón García, Maite Arroyo Villarino
Gastroenterología y Hepatología (English Edition).2020; 43(3): 126. CrossRef - Ustekinumab en enfermedad de Crohn: efectividad y seguridad en práctica clínica
Cristina Saldaña Dueñas, María Rullán Iriarte, Alfonso Elosua González, Cristina Rodríguez Gutiérrez, Saioa Rubio Iturria, Óscar Nantes Castillejo
Gastroenterología y Hepatología.2020; 43(9): 497. CrossRef - Real‐world long‐term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry
Marisa Iborra, Belén Beltrán, Agnes Fernández‐Clotet, Eva Iglesias‐Flores, Pablo Navarro, Montserrat Rivero, Ana Gutiérrez, Mónica Sierra‐Ausin, Francisco Mesonero, Rocío Ferreiro‐Iglesias, Joaquín Hinojosa, Xavier Calvet, Beatriz Sicilia, Carlos González
Alimentary Pharmacology & Therapeutics.2020; 52(6): 1017. CrossRef - Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn’s disease cohort
Clas-Göran af Björkesten, Tuire Ilus, Taru Hallinen, Erkki Soini, Anja Eberl, Kalle Hakala, Mikko Heikura, Airi Jussila, Ritva Koskela, Inka Koskinen, Veikko Moilanen, Christian Nielsen, Urpo Nieminen, Heikki Nuutinen, Markku Heikkinen, Ulla-Maija Suhonen
European Journal of Gastroenterology & Hepatology.2020; 32(12): 1507. CrossRef - Ustekinumab in Crohn's disease: Effectiveness and safety in clinical practice
Cristina Saldaña Dueñas, María Rullán Iriarte, Alfonso Elosua González, Cristina Rodríguez Gutiérrez, Saioa Rubio Iturria, Óscar Nantes Castillejo
Gastroenterología y Hepatología (English Edition).2020; 43(9): 497. CrossRef - Editorial: real‐world short‐term effectiveness of ustekinumab in 305 patients with Crohn’s disease—results from the ENEIDA registry. Authors' reply
Marisa Iborra, Belén Beltrán, Pilar Nos
Alimentary Pharmacology & Therapeutics.2019; 50(5): 600. CrossRef
- Comparative effectiveness and safety of ustekinumab at different intervals of maintenance phase in inflammatory bowel disease: a systematic review and meta-analysis
- 8,110 View
- 274 Download
- 15 Web of Science
- 19 Crossref
- Inflammatory bowel diseases
- Iranian Registry of Crohn’s and Colitis: study profile of first nation-wide inflammatory bowel disease registry in Middle East
- Masoud M Malekzadeh, Alireza Sima, Sudabeh Alatab, Anahita Sadeghi, Nasser Ebrahimi Daryani, Payman Adibi, Iradj Maleki, Hassan Vossoughinia, Hafez Fakheri, Abbas Yazdanbod, Seyed Alireza Taghavi, Rahim Aghazadeh, Mohammad Hassan Somi, Kazem Zendedel, Homayoon Vahedi, Reza Malekzadeh
- Intest Res 2019;17(3):330-339. Published online April 24, 2019
- DOI: https://doi.org/10.5217/ir.2018.00157
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
A recent study revealed increasing incidence and prevalence of inflammatory bowel disease (IBD) in Iran. The Iranian Registry of Crohn’s and Colitis (IRCC) was designed recently to answer the needs. We reported the design, methods of data collection, and aims of IRCC in this paper.
Methods
IRCC is a multicenter prospective registry, which is established with collaboration of more than 100 gastroenterologists from different provinces of Iran. Minimum data set for IRCC was defined according to an international consensus on standard set of outcomes for IBD. A pilot feasibility study was performed on 553 IBD patients with a web-based questionnaire. The reliability of questionnaire evaluated by Cronbach’s α.
Results
All sections of questionnaire had Cronbach’s α of more than 0.6. In pilot study, 312 of participants (56.4%) were male and mean age was 38 years (standard deviation=12.8) and 378 patients (68.35%) had ulcerative colitis, 303 subjects (54,7%) had college education and 358 patients (64.74%) were of Fars ethnicity. We found that 68 (12.3%), 44 (7.9%), 13 (2.3%) of participants were smokers, hookah and opium users, respectively. History of appendectomy was reported in 58 of patients (10.48%). The most common medication was 5-aminosalicylate (94.39%).
Conclusions
To the best of our knowledge, IRCC is the first national IBD registry in the Middle East and could become a reliable infrastructure for national and international research on IBD. IRCC will improve the quality of care of IBD patients and provide national information for policy makers to better plan for controlling IBD in Iran. -
Citations
Citations to this article as recorded by- Genomic testing identifies monogenic causes in patients with very early-onset inflammatory bowel disease: a multicenter survey in an Iranian cohort
Golnaz Eslamian, Mahnaz Jamee, Tooba Momen, Pejman Rohani, Sarehossadat Ebrahimi, Mehrnaz Mesdaghi, Soodeh Ghadimi, Mahboubeh Mansouri, Seyed Alireza Mahdaviani, Mahnaz Sadeghi-shabestari, Morteza Fallahpour, Bibi Shahin Shamsian, Narges Eslami, Samin Sha
Clinical and Experimental Immunology.2024; 217(1): 1. CrossRef - Sex and age differences in inflammatory bowel disease patients; a nationwide study based on Iranian Registry of Crohn’s and Colitis (IRCC)
Shaghayegh Khanmohammadi, Ali Sheidaei, Sudabeh Alatab, Ozra Tabatabaei-Malazy, Homayoon Vahedi, Fariborz Mansour-Ghanaei, Hafez Fakheri, Farshad Sheikhesmaeili, Anahita Sadeghi, Ali Reza Sima, Amir Anushiravan, Abbas Yazdanbod, Seyed Hamid Moosavy, Iradj
PLOS ONE.2024; 19(7): e0304792. CrossRef - Immunomodulatory effect of Dicrocoelium dendriticum ova on DSS-induced experimental colitis in C57BL/6 mouse
Leila Mighani, Malihe Eilakinezhad, Seyed-Alireza Esmaeili, Majid Khazaei, Moein Eskandari, Seyedeh Elnaz Nazari, Mojtaba Mousavi Bazaz, Khatereh kharazmi, Elham Moghaddas, Mehdi Zarean
Scientific Reports.2024;[Epub] CrossRef - The cost of illness analysis of inflammatory bowel disease
Majid Pakdin, Leila Zarei, Kamran Bagheri Lankarani, Sulmaz Ghahramani
BMC Gastroenterology.2023;[Epub] CrossRef - Iranian Consensus Guideline for Pharmacotherapy with Biologics and Small Molecules Drugs in Adults with Inflammatory Bowel Diseases
Niloofar Khoshnam-Rad, Homayoon Vahedi, Anahita Sadeghi, Mansoor Rastegarpanah, Soha Namazi, Amir Anushiravani, Ali Reza Sima, Shabnam Shahrokh, Sudabeh Alatab, Reza Malekzadeh
Middle East Journal of Digestive Diseases.2023; 15(2): 83. CrossRef - Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases
Bahar Saberzadeh-Ardestani, Amir Anushiravani, Fariborz Mansour-Ghanaei, Hafez Fakheri, Homayoon Vahedi, Farshad Sheikhesmaeili, Abbas Yazdanbod, Seyed Hamid Moosavy, Hasan Vosoghinia, Iradj Maleki, Siavosh Nasseri-Moghaddam, Bardia Khosravi, Masoud Malek
Inflammatory Bowel Diseases.2022; 28(7): 1004. CrossRef - Susceptibility of Patients with Inflammatory Bowel Disease to COVID-19 Compared with Their Households
Amir Anushiravani, Bahar Saberzadeh-Ardestani, Homayoon Vahedi, Hafez Fakheri, Fariborz Mansour-Ghanaei, Iraj Maleki, Siavosh Nasseri-Moghaddam, Hasan Vosoghinia, Mohammad Reza Ghadir, Ahmad Hormati, Amir Kasaeian, Amir Reza Radmard, Bardia Khosravi, Maso
Middle East Journal of Digestive Diseases.2022; 14(2): 182. CrossRef - Risk Factors Affecting 90-day Readmission of Patients with Inflammatory Bowel Disease
Sulmaz Ghahramani, Zahra Tamartash, Mohammad Sayari, Homayoun Vahedi, Fatemeh Karimian, Sadegh Heydari, Kamran Bagheri Lankarani
Middle East Journal of Digestive Diseases.2022; 14(1): 34. CrossRef - What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef - The clinical significance of biliary findings in magnetic resonance enterography of patients with inflammatory bowel disease
Sara Momtazmanesh, Mehran Gholami, Neda Pak, Ali Reza Sima, Seyed Ali Montazeri, Shadi Kolahdoozan, Homayoun Vahedi, Amir Reza Radmard
Polish Journal of Radiology.2022; 87: 613. CrossRef - Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Ajit Sood, Kirandeep Kaur, Ramit Mahajan, Vandana Midha, Arshdeep Singh, Sarit Sharma, Amarender Singh Puri, Bhabhadev Goswami, Devendra Desai, C. Ganesh Pai, Kiran Peddi, Mathew Philip, Rakesh Kochhar, Sandeep Nijhawan, Shobna Bhatia, N. Sridhara Rao
Intestinal Research.2021; 19(2): 206. CrossRef - Enteroscopy in Crohn’s Disease: Are There Any Changes in Role or Outcomes Over Time? A KASID Multicenter Study
Seong Ran Jeon, Jin-Oh Kim, Jeong-Sik Byeon, Dong-Hoon Yang, Bong Min Ko, Hyeon Jeong Goong, Hyun Joo Jang, Soo Jung Park, Eun Ran Kim, Sung Noh Hong, Jong Pil Im, Seong-Eun Kim, Ja Seol Koo, Chang Soo Eun, Dong Kyung Chang
Gut and Liver.2021; 15(3): 375. CrossRef - Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Association of LRRK2 rs11564258 single nucleotide polymorphisms with type and extent of gastrointestinal mycobiome in ulcerative colitis: a case–control study
Niusha Sharifinejad, Seyed Hamidreza Mozhgani, Mahmood Bakhtiyari, Elaheh Mahmoudi
Gut Pathogens.2021;[Epub] CrossRef - Anti-TNF containing regimens may be associated with increased risk of Clostridioides difficile infection in patients with underlying inflammatory bowel disease
Fahimeh Sadat Gholam-Mostafaei, Abbas Yadegar, Hamid Asadzadeh Aghdaei, Masoumeh Azimirad, Nasser Ebrahimi Daryani, Mohammad Reza Zali
Current Research in Translational Medicine.2020; 68(3): 125. CrossRef
- Genomic testing identifies monogenic causes in patients with very early-onset inflammatory bowel disease: a multicenter survey in an Iranian cohort
- 8,240 View
- 193 Download
- 17 Web of Science
- 16 Crossref
- Endoscopy
- Efficacy and safety of cold forceps polypectomy utilizing the jumbo cup: a prospective study
- Hiroshi Hasegawa, Shigeki Bamba, Kenichiro Takahashi, Masaki Murata, Taketo Otsuka, Hiroshi Matsumoto, Takehide Fujimoto, Rie Osak, Hirotsugu Imaeda, Atsushi Nishida, Hiromitsu Ban, Ayano Sonoda, Osamu Inatomi, Masaya Sasaki, Mitsushige Sugimoto, Akira Andoh
- Intest Res 2019;17(2):265-272. Published online November 28, 2018
- DOI: https://doi.org/10.5217/ir.2018.00103
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
There are few prospective studies on cold forceps polypectomy (CFP) using jumbo cup forceps. Therefore, we examined patients with diminutive polyps (5 mm or smaller) treated with CFP using jumbo cup forceps to achieve an adenoma-free colon and also assessed the safety of the procedure and the recurrence rate of missed or residual polyp after CFP by performing follow-up colonoscopy 1 year later.
Methods
We included patients with up to 5 adenomas removed at initial colonoscopy and analyzed data from a total of 361 patients with 573 adenomas. One-year follow-up colonoscopy was performed in 165 patients, at which 251 lesions were confirmed.
Results
The one-bite resection rate with CFP was highest for lesions 3 mm or smaller and decreased significantly with increasing lesion size. Post-procedural hemorrhage was observed in 1 of 573 lesions (0.17%). No perforation was noted. The definite recurrence rate was 0.8% (2/251 lesions). The probable recurrence rate, which was defined as recurrence in the same colorectal segment, was 17%. Adenoma-free colon was achieved in 55% of patients at initial resection. Multivariate analysis revealed that achievement of an adenoma-free colon was significantly associated with number of adenomas and years of endoscopic experience.
Conclusions
CFP using jumbo biopsy forceps was safe and showed a high one-bite resection rate for diminutive lesions of 3 mm or smaller. The low definite recurrence rate confirms the reliability of CFP using jumbo biopsy forceps. Number of adenomas and years of endoscopic experience were key factors in achieving an adenoma-free colon. -
Citations
Citations to this article as recorded by- Polypectomy for Diminutive and Small Colorectal Polyps
Melissa Zarandi-Nowroozi, Roupen Djinbachian, Daniel von Renteln
Gastrointestinal Endoscopy Clinics of North America.2022; 32(2): 241. CrossRef - Cold Snare Resection of Colorectal Polyps: Updates and Recent Developments
Roupen Djinbachian, Daniel von Renteln
Current Treatment Options in Gastroenterology.2022; 20(3): 221. CrossRef - Prospective multicenter study of the efficacy and safety of cold forceps polypectomy for ≤ 6-mm non-ampullary duodenal low-grade adenomas
Hiromitsu Kanzaki, Joichiro Horii, Ryuta Takenaka, Hiroyuki Nakagawa, Kazuhiro Matsueda, Takao Tsuzuki, Masahide Kita, Yasushi Yamasaki, Takehiro Tanaka, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Jun Tomoda, Hiroyuki Okada
Endoscopy International Open.2022; 10(06): E712. CrossRef - Endoscopic resection of local recurrences of diminutive polyps by cold forceps polypectomy
Toshio Kuwai, Takuya Yamada, Tatsuya Toyokawa, Tomohiro Kudo, Naoki Esaka, Hajime Ohta, Haruhiro Yamashita, Yasuo Hosoda, Noriko Watanabe, Naohiko Harada
Scandinavian Journal of Gastroenterology.2021; 56(3): 363. CrossRef - How to Approach Small Polyps in Colon: Tips and Tricks
Sultan Mahmood, Enrik John Aguila, Asad ur Rahman, Asim Shuja, Steven Bollipo
Techniques and Innovations in Gastrointestinal Endoscopy.2021; 23(4): 328. CrossRef - Risk factors for incomplete polyp resection during colonoscopy
Weifeng Lao, Pankaj Prasoon, Gaoyang Cao, Lian Tat Tan, Sheng Dai, Giridhar Hanumappa Devadasar, Xuefeng Huang
Laparoscopic, Endoscopic and Robotic Surgery.2021;[Epub] CrossRef - Rates of Incomplete Resection of 1- to 20-mm Colorectal Polyps: A Systematic Review and Meta-Analysis
Roupen Djinbachian, Ryma Iratni, Madeleine Durand, Paola Marques, Daniel von Renteln
Gastroenterology.2020; 159(3): 904. CrossRef - Child-Pugh B or C Cirrhosis Increases the Risk for Bleeding Following Colonoscopic Polypectomy
Hosim Soh, Jaeyoung Chun, Seung Wook Hong, Seona Park, Yun Bin Lee, Hyun Jung Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jong Pil Im, Yoon Jun Kim, Joo Sung Kim, Jung-Hwan Yoon
Gut and Liver.2020; 14(6): 755. CrossRef
- Polypectomy for Diminutive and Small Colorectal Polyps
- 10,049 View
- 175 Download
- 7 Web of Science
- 8 Crossref
- Colorectal neoplasia
- Development and validation of a scoring system for advanced colorectal neoplasm in young Korean subjects less than age 50 years
- Ji Yeon Kim, Sungkyoung Choi, Taesung Park, Seul Ki Kim, Yoon Suk Jung, Jung Ho Park, Hong Joo Kim, Yong Kyun Cho, Chong Il Sohn, Woo Kyu Jeon, Byung Ik Kim, Kyu Yong Choi, Dong Il Park
- Intest Res 2019;17(2):253-264. Published online November 20, 2018
- DOI: https://doi.org/10.5217/ir.2018.00062
-
Abstract
PDFPubReaderePub
- Background/Aims
Colorectal cancer incidence among patients aged ≤50 years is increasing. This study aimed to develop and validate an advanced colorectal neoplasm (ACRN) screening model for young adults aged <50 years in Korea.
Methods
This retrospective cross-sectional study included 59,575 consecutive asymptomatic Koreans who underwent screening colonoscopy between 2003 and 2012 at a single comprehensive health care center. Young Adult Colorectal Screening (YCS) score was developed as an optimized risk stratification model for ACRN using multivariate analysis and was internally validated. The predictive power and diagnostic performance of YCS score was compared with those of Asia-Pacific Colorectal Screening (APCS) and Korean Colorectal Screening (KCS) scores.
Results
41,702 and 17,873 subjects were randomly allocated into the derivation and validation cohorts, respectively, by examination year. ACRN prevalence was 0.9% in both cohorts. YCS score comprised sex, age, alcohol, smoking, obesity, glucose metabolism abnormality, and family history of CRC, with score ranges of 0 to 10. In the validation cohort, ACRN prevalence was 0.6% in the low-risk tier (score, 0–4), 1.5% in the moderate-risk tier (score, 5–7), and 3.4% in the high-risk tier (score, 8–10). ACRN risk increased 2.5-fold (95%CI, 1.8–3.4) in the moderate-risk tier and 5.8-fold (95%CI, 3.4–9.8) in the high-risk tier compared with the low-risk tier. YCS score identified better balanced accuracy (53.9%) than APCS (51.5%) and KCS (50.7%) scores and had relatively good discriminative power (area under the curve=0.660).
Conclusions
YCS score based on clinical and laboratory risk factors was clinically effective and beneficial for predicting ACRN risk and targeting screening colonoscopy in adults aged <50 years. -
Citations
Citations to this article as recorded by- Performance of the Asia–Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review
Mai Ngoc Luu, Nhi Ai Trinh, Truc Le Thanh Tran, Thinh Phuong Dang, Toru Hiyama, Duc Trong Quach
Journal of Gastroenterology and Hepatology.2024; 39(6): 1000. CrossRef - Response to commentaries on “Performance of the Asia‐Pacific colorectal screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review”
MN Luu, DT Quach
Journal of Gastroenterology and Hepatology.2024;[Epub] CrossRef - Family History of Colorectal Cancer and the Risk of Colorectal Neoplasia: A Systematic Review and Meta-Analysis
Kai Gao, Huyi Jin, Yi Yang, Jiayu Li, Yuanliang He, Ruiyao Zhou, Wanting Zhang, Xiangrong Gao, Zongming Yang, Mengling Tang, Jianbing Wang, Ding Ye, Kun Chen, Mingjuan Jin
American Journal of Gastroenterology.2024;[Epub] CrossRef - Updated epidemiology of gastrointestinal cancers in East Asia
Junjie Huang, Don Eliseo Lucero-Prisno, Lin Zhang, Wanghong Xu, Sunny H. Wong, Siew C. Ng, Martin C. S. Wong
Nature Reviews Gastroenterology & Hepatology.2023; 20(5): 271. CrossRef - From Algorithms to Clinical Utility: A Systematic Review of Individualized Risk Prediction Models for Colorectal Cancer
Deborah Jael Herrera, Wessel van de Veerdonk, Daiane Maria Seibert, Moges Muluneh Boke, Claudia Gutiérrez-Ortiz, Nigus Bililign Yimer, Karen Feyen, Allegra Ferrari, Guido Van Hal
Gastrointestinal Disorders.2023; 5(4): 549. CrossRef - Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef - Is early-onset cancer an emerging global epidemic? Current evidence and future implications
Tomotaka Ugai, Naoko Sasamoto, Hwa-Young Lee, Mariko Ando, Mingyang Song, Rulla M. Tamimi, Ichiro Kawachi, Peter T. Campbell, Edward L. Giovannucci, Elisabete Weiderpass, Timothy R. Rebbeck, Shuji Ogino
Nature Reviews Clinical Oncology.2022; 19(10): 656. CrossRef - Strategies for colorectal cancer screening and post-polypectomy surveillance for young adults under age 50
Yoon Suk Jung
Precision and Future Medicine.2021; 5(2): 69. CrossRef - How to Choose the Optimal Bowel Preparation Regimen for Colonoscopy
Ji Eun Na, Eun Ran Kim
The Ewha Medical Journal.2021; 44(4): 122. CrossRef - The Role of Diet and Lifestyle in Early-Onset Colorectal Cancer: A Systematic Review
Marta Puzzono, Alessandro Mannucci, Simone Grannò, Raffaella Alessia Zuppardo, Andrea Galli, Silvio Danese, Giulia Martina Cavestro
Cancers.2021; 13(23): 5933. CrossRef - Association between waist circumference and risk of colorectal neoplasia in normal‐weight adults
Yoon Suk Jung, Nam Hee Kim, Hyo‐Joon Yang, Soo‐Kyung Park, Jung Ho Park, Dong Il Park, Chong Il Sohn
Journal of Gastroenterology and Hepatology.2020; 35(1): 43. CrossRef - Risk prediction rule for advanced neoplasia on screening colonoscopy for average-risk individuals
Ala I Sharara, Ali El Mokahal, Ali H Harb, Natalia Khalaf, Fayez S Sarkis, Mustapha M El-Halabi, Nabil M Mansour, Ahmad Malli, Robert Habib
World Journal of Gastroenterology.2020; 26(37): 5705. CrossRef - Risk Factors Associated With Young-Onset Colorectal Adenomas and Cancer: A Systematic Review and Meta-Analysis of Observational Research
Genevieve Breau, Ursula Ellis
Cancer Control.2020;[Epub] CrossRef - Prevalence and risk factors of colorectal cancer in Asia
Martin CS Wong, Hanyue Ding, Jingxuan Wang, Paul SF Chan, Junjie Huang
Intestinal Research.2019; 17(3): 317. CrossRef
- Performance of the Asia–Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: A meta‐analysis and systematic review
- 8,753 View
- 165 Download
- 12 Web of Science
- 14 Crossref
- IBD
- The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile
- Huei-Wen Lim, Isaiah P. Schuster, Ramona Rajapakse, Farah Monzur, Sundas Khan, Keith Sultan
- Intest Res 2019;17(2):244-252. Published online February 12, 2019
- DOI: https://doi.org/10.5217/ir.2018.00101
-
Abstract
PDFPubReaderePub
- Background/Aims
Optimal management of inflammatory bowel disease (IBD) with concomitant Clostridium difficile infection (CDI) is controversial, especially when CDI diagnosis is made by polymerase chain reaction (PCR) testing, which may reflect colonization without infection.
Methods
We performed a multicenter review of all inpatients with IBD and PCR diagnosed CDI. Outcomes included length of stay, 30- and 90-day readmission, colectomy during admission and within 3 months, intensive care unit (ICU) admission, CDI relapse and death for patients who received corticosteroid (CS) after CDI diagnosis versus those that did not. Propensity-adjusted regression analysis of outcomes based on CS usage was performed.
Results
We identified 177 IBD patients with CDI, 112 ulcerative colitis and 65 Crohn’s disease. For IBD overall, CS after CDI diagnosis was associated with prolonged hospitalization (5.5 days: 95% confidence interval [CI], 1.5–9.6 days; P=0.008), higher colectomy rate within 3 months (odds ratio [OR], 5.5; 95% CI, 1.1–28.2; P=0.042) and more frequent ICU admissions (OR, 7.8; 95% CI, 1.5–41.6; P=0.017) versus no CS. CS use post-CDI diagnosis in UC patients was associated with prolonged hospitalization (6.2 days: 95% CI, 0.4– 12.0 days; P=0.036) and more frequent ICU admissions (OR, 7.4; 95% CI, 1.1–48.7; P=0.036).
Conclusions
CS use among IBD inpatients with CDI diagnosed by PCR is associated with poorer outcomes and would seem to reinforce the importance of C. difficile toxin assay to help distinguish colonization from infection. This adverse effect appears more prominent among those with UC. -
Citations
Citations to this article as recorded by- Clostridioides difficile infection in inflammatory bowel disease: a clinical review
Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen
Expert Review of Anti-infective Therapy.2024; 22(5): 297. CrossRef - The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases
Alina Boeriu, Adina Roman, Crina Fofiu, Daniela Dobru
Pathogens.2022; 11(7): 819. CrossRef - Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
Intestinal Research.2022; 20(4): 431. CrossRef - KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 105. CrossRef
- Clostridioides difficile infection in inflammatory bowel disease: a clinical review
- 9,073 View
- 171 Download
- 4 Web of Science
- 4 Crossref
- IBD
- Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity
- Ko Eun Lee, Sung-Ae Jung, Sang Hyoung Park, Chang Mo Moon, So Yeon Shim, Eun Soo Kim, Su Jin Cho, Seong-Eun Kim, Kwang Bum Cho, Suk-Kyun Yang
- Intest Res 2019;17(2):237-243. Published online February 8, 2019
- DOI: https://doi.org/10.5217/ir.2018.00071
-
Abstract
PDFPubReaderePub
- Background/Aims
The onset of inflammatory bowel disease (IBD) usually occurs at young age, and therefore, women IBD patients experience pregnancy during their disease progression. Recently, the use of anti-tumor necrosis factor-α (anti-TNF-α) has been rapidly increasing. The aim of this study was to evaluate pregnancy related outcomes in women with IBD who were treated with anti-TNF-α during pregnancy and immunity of their children.
Methods
Korean women with IBD who had been treated with anti-TNF-α during pregnancy had been enrolled. Medical records were reviewed and a survey was performed for each patient. For the patients who agreed on additional examination for their children, children’s growth, medical history and antibody to hepatitis B surface antigen (anti-HBs) titer were checked.
Results
All 18 patients had been diagnosed with Crohn’s disease. There was not any case of preterm delivery, low birth-weight infant, congenital anomaly, nor stillbirth. All 12 children had followed the regular vaccination schedule for hepatitis B and 4 of them showed negative results for anti-HBs. After the 1 booster vaccination, all children demonstrated seroconversion. Regarding live vaccines, 4 children had bacillus Calmette-Guerin and 4 had rotavirus vaccine before 6 months, without any specific side effects.
Conclusions
This was the first study of immunity of the children born from IBD women who had been treated with anti-TNF-α medication during their pregnancy. IBD women had comparable pregnancy outcomes with the general women population, suggesting that the disease activity rather than the administered medication would be more important in healthy pregnancy. Considering the history of vaccination and anti-HBs titers, immunity seems to be intact in the children. -
Citations
Citations to this article as recorded by- Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera
Inflammatory Bowel Diseases.2024;[Epub] CrossRef - Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review
Paula Sousa, Javier P Gisbert, Mette Julsgaard, Christian Philipp Selinger, María Chaparro
Journal of Crohn's and Colitis.2024; 18(Supplement): ii16. CrossRef - 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
Arthritis & Rheumatology.2023; 75(3): 333. CrossRef - 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
Arthritis Care & Research.2023; 75(3): 449. CrossRef - Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy
Robert Silver, Sabrina Craigo, Flint Porter, Sarah S. Osmundson, Jeffrey A. Kuller, Mary E. Norton
American Journal of Obstetrics and Gynecology.2023; 228(3): B41. CrossRef - Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe?
Javier P Gisbert, María Chaparro
Journal of Crohn's and Colitis.2023; 17(6): 995. CrossRef - Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)
B. S. Belov, N. V. Muravyeva, E. L. Nasonov
Rheumatology Science and Practice.2023; 61(2): 151. CrossRef - Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
Soo Min Ahn, Young Bin Joo, Yun Jin Kim, So-Young Bang, Hye-Soon Lee
Journal of Korean Medical Science.2023;[Epub] CrossRef - Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts
B. S. Belov, N. V. Muravyeva
Antibiotics and Chemotherapy.2023; 68(5-6): 77. CrossRef - Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants
Helene Chiarella-Redfern, Sangmin Lee, Bellal Jubran, Nastaran Sharifi, Remo Panaccione, Cora Constantinescu, Eric I Benchimol, Cynthia H Seow
Inflammatory Bowel Diseases.2022; 28(1): 79. CrossRef - A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero
Bethan Goulden, Nicole Chua, Elaine Parker, Ian Giles
Rheumatology.2022; 61(10): 3902. CrossRef - The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Kristel K Leung, Parul Tandon, Vivek Govardhanam, Cynthia Maxwell, Vivian Huang
Inflammatory Bowel Diseases.2021; 27(4): 550. CrossRef - The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Min-A Kim, Young-Han Kim, Jaeyoung Chun, Hye Sun Lee, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Jae Jun Park
Journal of Crohn's and Colitis.2021; 15(5): 719. CrossRef - Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road
Asmaa Beltagy, Azin Aghamajidi, Laura Trespidi, Wally Ossola, Pier Luigi Meroni
Frontiers in Pharmacology.2021;[Epub] CrossRef - ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
Journal of Crohn's and Colitis.2021; 15(6): 879. CrossRef - Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Eric I. Benchimol, Frances Tse, Matthew W. Carroll, Jennifer C. deBruyn, Shelly A. McNeil, Anne Pham-Huy, Cynthia H. Seow, Lisa L. Barrett, Talat Bessissow, Nicholas Carman, Gil Y. Melmed, Otto G. Vanderkooi, John K. Marshall, Jennifer L. Jones
Gastroenterology.2021; 161(2): 669. CrossRef - Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Eric I Benchimol, Frances Tse, Matthew W Carroll, Jennifer C deBruyn, Shelly A McNeil, Anne Pham-Huy, Cynthia H Seow, Lisa L Barrett, Talat Bessissow, Nicholas Carman, Gil Y Melmed, Otto G Vanderkooi, John K Marshall, Jennifer L Jones
Journal of the Canadian Association of Gastroenterology.2021; 4(4): e59. CrossRef - Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease
Parul Tandon, Vivek Govardhanam, Kristel Leung, Cynthia Maxwell, Vivian Huang
Alimentary Pharmacology & Therapeutics.2020; 51(3): 320. CrossRef - Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease
Sang Hyoung Park, Hyo Jong Kim, Chang Kyun Lee, Eun Mi Song, Sang-Bum Kang, Byung Ik Jang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Eun Young Kim, Yun Jin Jung, Soo-Kyung Park, Dong Il Park, Byong Duk Ye, Sung-Ae Jung, Suk-Kyun Yang
Journal of Crohn's and Colitis.2020; 14(12): 1780. CrossRef - Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef
- Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
- 8,515 View
- 227 Download
- 17 Web of Science
- 20 Crossref
- IBD
- Abdominal ultrasonography with color Doppler analysis in the assessment of ileal Crohn’s disease: comparison with magnetic resonance enterography
- Antonio Carlos da Silva Moraes, Glycia de Freitas Moraes, Antonio Luis Eiras de Araújo, Ronir Raggio Luiz, Celeste Elia, Antonio Jose Carneiro, Heitor Siffert Pereira de Souza
- Intest Res 2019;17(2):227-236. Published online April 10, 2019
- DOI: https://doi.org/10.5217/ir.2018.00124
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Consistently defining disease activity remains a critical challenge in the follow-up of patients with Crohn’s disease (CD). We investigated the potential applicability of abdominal ultrasonography with color Doppler (USCD) analysis for the detection of morphological alterations and inflammatory activity in CD.
Methods
Forty-three patients with CD ileitis/ileocolitis were evaluated using USCD analysis with measurements obtained on the terminal ileum and right colon. Sonographic parameters included wall thickening, stricture, hyperemia, presence of intra-abdominal mass, and fistulas. Patients were evaluated for the clinical activity (Harvey-Bradshaw Index [HBI]), fecal calprotectin (FC) and C-reactive protein (CRP). The USCD performance was assessed using magnetic resonance enterography (MRE) as a criterion standard.
Results
Most measurements obtained with USCD matched the data generated with MRE; however, the agreement improved in clinically active patients where sensitivity, positive predictive value, and accuracy were >80%, considering wall thickening and hyperemia. Complications such as intestinal wall thickening, stricture formation, and hyperemia, were detected in the USCD analysis with moderate agreement with MRE. The best agreement with the USCD analysis was obtained in regard to FC, where the sensitivity, positive predictive value, and accuracy were >70%. The overall performance of USCD was superior to that of HBI, FC and CRP levels, particularly when considering thickening, stricture, and hyperemia parameters.
Conclusions
USCD represents a practical noninvasive and low-cost tool for evaluating patients with ileal or ileocolonic disease, particularly in clinically active CD. Therefore, USCD might become a useful asset in the follow-up of patients with CD. -
Citations
Citations to this article as recorded by- Diagnostic Accuracy of Intestinal Ultrasound in the Detection of Intra-Abdominal Complications in Crohn’s Disease: A Systematic Review and Meta-Analysis
Maarten J Pruijt, Floris A E de Voogd, Nahid S M Montazeri, Faridi S van Etten-Jamaludin, Geert R D’Haens, Krisztina B Gecse
Journal of Crohn's and Colitis.2024; 18(6): 958. CrossRef - Comparative study between ultrasound and MR enterography in evaluation of Crohn’s disease
Nada Sayed Mahdy, Sahar Mohammed El-Gaafary, Khaled Hamdy Abdel Mageed, Khaled A. Ali Shehata, Maha Ahmed Sayed AbdelKarim, Essam Mohamed Abdulhafiz
Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub] CrossRef - Could ultrasound alone substitute MR imaging in evaluation of Crohn’s disease complications?
Hany El-Assaly, Asmaa Abdel Baky Mohamed, Hesham Adel Abdel Fattah Mustafa
Egyptian Journal of Radiology and Nuclear Medicine.2024;[Epub] CrossRef - Radiology plus ileocolonoscopy versus radiology alone in Crohn’s disease: prognosis prediction and mutual agreement
Hye Kyung Hyun, Jongwook Yu, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(3): 567. CrossRef - Comparison of Diagnostic Performance of Ultrasonography and Magnetic Resonance Enterography in the Assessment of Active Bowel Lesions in Patients with Crohn’s Disease: A Systematic Review and Meta-Analysis
Da In Lee, Myung-Won You, So Hyun Park, Mirinae Seo, Seong Jin Park
Diagnostics.2022; 12(8): 2008. CrossRef - Fistulizing Crohn's disease
Amy L. Lightner, Jean H. Ashburn, Mantaj S. Brar, Michele Carvello, Pramodh Chandrasinghe, Anthony de Buck van Overstraeten, Phillip R. Fleshner, Gaetano Gallo, Paulo Gustavo Kotze, Stefan D. Holubar, Lillian M. Reza, Antonino Spinelli, Scott A. Strong, P
Current Problems in Surgery.2020; 57(11): 100808. CrossRef
- Diagnostic Accuracy of Intestinal Ultrasound in the Detection of Intra-Abdominal Complications in Crohn’s Disease: A Systematic Review and Meta-Analysis
- 8,083 View
- 143 Download
- 6 Web of Science
- 6 Crossref
- IBD
- Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
- Shinji Okabayashi, Taku Kobayashi, Eiko Saito, Takahiko Toyonaga, Ryo Ozaki, Shintaro Sagami, Masaru Nakano, Junichi Tanaka, Keiji Yagisawa, Satoshi Kuronuma, Osamu Takeuchi, Toshifumi Hibi
- Intest Res 2019;17(2):218-226. Published online February 7, 2019
- DOI: https://doi.org/10.5217/ir.2018.00117
-
Abstract
PDFPubReaderePub
- Background/Aims
The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range of optimal dosages, depending on their CYP3A5 expression status. Here, we evaluated whether individualization of TAC dosages based on CYP3A5 SNPs would improve its therapeutic efficacy in ulcerative colitis.
Methods
Twenty-one patients were prospectively treated, with their initial dosage adjusted according to their CYP3A5 status (0.1, 0.15, and 0.2 mg/kg/day for CYP3A5*3/*3, CYP3A5*1/*3, and CYP3A5*1/*1, respectively). Their clinical outcomes were compared with those of patients treated with a fixed dose (0.1 mg/kg/day).
Results
The first blood trough level of CYP3A5 expressors, CYP3A5*1/*3 or CYP3A5*1/*1, and the overall rate in achieving the target blood trough level within a week in the individualized-dose group were significantly higher than those in the fixed-dose group (5.15±2.33 ng/mL vs. 9.63±0.79 ng/mL, P=0.035 and 12.5% vs. 66.7%, P=0.01). The remission rate at 2 weeks in the expressors was as high as that in the nonexpressors, CYP3A5*3/*3, in the individualized-dose group.
Conclusions
Individualized TAC treatment is effective against ulcerative colitis regardless of the CYP3A5 genotype. -
Citations
Citations to this article as recorded by- The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
Maizumi Furuse, Shuhei Hosomi, Yu Nishida, Shigehiro Itani, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuaki Nagami, Koichi Taira, Noriko Kamata, Toshio Watanabe, Kenji Watanabe, Yasuhiro Fujiwara, Erika Cecchin
PLOS ONE.2021; 16(4): e0250597. CrossRef - Advances in research of tacrolimus for treatment of inflammatory bowel disease
Jing-Jing Wang, Yi-Hong Fan
World Chinese Journal of Digestology.2019; 27(13): 842. CrossRef
- The impact of cytochrome P450 3A genetic polymorphisms on tacrolimus pharmacokinetics in ulcerative colitis patients
- 7,373 View
- 148 Download
- 1 Web of Science
- 2 Crossref
- IBD
- The effect of vitamin D administration on inflammatory markers in patients with inflammatory bowel disease
- Jae Chang Jun, Hyuk Yoon, Yoon Jin Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim
- Intest Res 2019;17(2):210-217. Published online November 27, 2018
- DOI: https://doi.org/10.5217/ir.2018.00081
-
Abstract
PDFPubReaderePub
- Background/Aims
The exact relationship between vitamin D deficiency and inflammatory bowel disease (IBD) remains unclear. We evaluated the effect of vitamin D3 administration on inflammatory responses and disease severity in patients with IBD.
Methods
We investigated the serum 25-hydroxyvitamin D3 [25-(OH)D] and C-reactive protein (CRP) levels and the partial Mayo score (PMS) in patients with IBD. Vitamin D3 was administered in patients with either vitamin D deficiency or insufficiency and CRP serum vitamin D levels and PMS were re-examined at 6 months of administration.
Results
In 88 patients with Crohn’s disease (CD), a negative correlation was found between serum vitamin D and CRP. In 178 patients with ulcerative colitis (UC), serum vitamin D showed no association with CRP or PMS. Serum vitamin D increased from 11.08±3.63 to 22.69±6.11 ng/mL in 29 patients with CD and from 11.45±4.10 to 24.20±6.61 ng/mL in 41 patients with UC who received vitamin D3 treatment (P<0.001 and P<0.001, respectively). In patients with CD, median ΔCRP was –0.24 in the normalized vitamin D group and –0.11 in the non-normalized group (P=0.308). In patients with UC, median ΔCRP was −0.01 in the normalized vitamin D group and 0.06 in the non-normalized group (P=0.359).
Conclusions
Although a negative correlation was found between serum vitamin D and CRP levels in patients with CD, administration of vitamin D did not improve the CRP level in patients with CD. In patients with UC, serum vitamin D level was unrelated to CRP or PMS. -
Citations
Citations to this article as recorded by- The use of vitamin D for patients with inflammatory bowel diseases
Júlia Novaes Matias, Vinícius Marinho Lima, Giovanna Soares Nutels, Lucas Fornari Laurindo, Sandra Maria Barbalho, Ricardo de Alvares Goulart, Adriano Cressoni Araújo, Rodrigo Buzinaro Suzuki, Elen Landgraf Guiguer
International Journal for Vitamin and Nutrition Research.2024; 94(1): 54. CrossRef - The effect of vitamin D serum levels on the values of C-reactive protein and fecal calprotectin in patients with ulcerative colitis in clinical remission
Zarko Krnetic, Tijana Icin, Zeljka Savic, Olgica Latinovic Bosnjak, Vladimir Vracaric, Dimitrije Damjanov, Tatiana Jocic, Radoslav Pejin, Nebojsa Janjic
Vojnosanitetski pregled.2024; 81(10): 619. CrossRef - Low Vitamin K and Vitamin D Dietary Intake in Patients with Inflammatory Bowel Diseases
Filippo Vernia, Giorgia Burrelli Scotti, Noemi Sara Bertetti, Giuseppe Donato, Stefano Necozione, Piero Vernia, Nadia Pallotta
Nutrients.2023; 15(7): 1678. CrossRef - High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases
Hyung Jin Ahn, Ye-Jee Kim, Ho-Su Lee, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Beom-Jun Kim, Sang Hyoung Park
Clinical Gastroenterology and Hepatology.2022; 20(5): e1022. CrossRef - High Dose Intramuscular Vitamin D3 Supplementation Impacts the Gut Microbiota of Patients With Clostridioides Difficile Infection
Sang Hoon Lee, Han-Ki Park, Chang Don Kang, Dae Hee Choi, Sung Chul Park, Jin Myung Park, Seung-Joo Nam, Gi Bong Chae, Kyoung yul Lee, Hyunseok Cho, Sung Joon Lee
Frontiers in Cellular and Infection Microbiology.2022;[Epub] CrossRef - Influence of Severe Vitamin D Deficiency on the Clinical Course of Inflammatory Bowel Disease
Nam Seok Ham, Sung Wook Hwang, Eun Hye Oh, Jeongseok Kim, Ho-Su Lee, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang
Digestive Diseases and Sciences.2021; 66(2): 587. CrossRef - Effects of a Single Oral Megadose of Vitamin D3 on Inflammation and Oxidative Stress Markers in Overweight and Obese Women: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Laine de Carvalho Guerra Pessoa Mamede, Rafaela Lira Formiga Cavalcanti de Lima, Alexandre Sérgio Silva, João Carlos Lima Rodrigues Pita, Nadjeanny Ingrid Galdino Gomes, Elisama Araújo de Sena, Rhayra Priscila Moraes Nobrega, João Otávio Scarano Alcântara
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 525. CrossRef - The 25(OH)D3, but Not 1,25(OH)2D3 Levels Are Elevated in IBD Patients Regardless of Vitamin D Supplementation and Do Not Associate with Pain Severity or Frequency
Anna Zielińska, Aleksandra Sobolewska-Włodarczyk, Maria Wiśniewska-Jarosińska, Anita Gąsiorowska, Jakub Fichna, Maciej Sałaga
Pharmaceuticals.2021; 14(3): 284. CrossRef - The effects of consuming a low-fat yogurt fortified with nano encapsulated vitamin D on serum pro-oxidant-antioxidant balance (PAB) in adults with metabolic syndrome; a randomized control trial
Niloofar Taghizadeh, Payam Sharifan, Mansoureh Sadat Ekhteraee Toosi, Fatemeh Najar Sedgh Doust, Susan Darroudi, Asma Afshari, Mitra Rezaie, Mohamad Safarian, Hassan Vatanparast, Saeed Eslami, Hamideh Ghazizadeh, Zahra Khorasanchi, Mohammad Bagherniya, Go
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2021; 15(6): 102332. CrossRef - Vitamin D and inflammatory bowel disease: what do we know so far?
Antonio María Caballero Mateos, Raúl Vicente Olmedo-Martín, Amparo Roa-Colomo, María del Mar Díaz Alcázar, Manuel Valenzuela Barranco
Revista Española de Enfermedades Digestivas.2020;[Epub] CrossRef - Inflammatory Bowel Disease and Vitamin D
Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon
The Korean Journal of Gastroenterology.2020; 76(6): 275. CrossRef - Vitamin D in Inflammatory Bowel Disease: Biological, Clinical and Therapeutic Aspects
Raúl Vicente Olmedo-Martín, Inmaculada González-Molero, Gabriel Olveira, Víctor Amo-Trillo, Miguel Jiménez-Pérez
Current Drug Metabolism.2019; 20(5): 390. CrossRef - Intraluminal Farnesol and Farnesal in the Mealworm's Alimentary Canal: An Unusual Storage Site Uncovering Hidden Eukaryote Ca2+-Homeostasis-Dependent “Golgicrine” Activities
Arnold De Loof, Liliane Schoofs
Frontiers in Endocrinology.2019;[Epub] CrossRef
- The use of vitamin D for patients with inflammatory bowel diseases
- 7,279 View
- 220 Download
- 17 Web of Science
- 13 Crossref
- IBD
- The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces
- Sakiko Hiraoka, Shiho Takashima, Toshihiro Inokuchi, Asuka Nakarai, Masahiro Takahara, Keita Harada, Yasuhiro Seki, Katsunori Watanabe, Jun Kato, Hiroyuki Okada
- Intest Res 2019;17(2):202-209. Published online December 14, 2018
- DOI: https://doi.org/10.5217/ir.2018.00086
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Fecal calprotectin (Fcal) as well as the fecal immunochemical test (FIT) are useful biomarkers for detecting activity and mucosal healing in inflammatory bowel diseases. Here, we report the performance of simultaneous measurements of Fcal and FIT for ulcerative colitis (UC) patients using the newly-developed latex agglutination turbidimetric immunoassay (LATIA) system.
Methods
Fcal and hemoglobin were measured by the LATIA system in 152 UC patients who underwent colonoscopy. Fcal was also quantified with a conventional enzyme-linked immunosorbent assay (ELISA). Fecal markers were evaluated in conjunction with the mucosal status of UC, which was assessed via the Mayo endoscopic subscore (MES) classification.
Results
The LATIA system could quantify calprotectin and hemoglobin simultaneously with the same fecal samples within 10 minutes. The values of the Fcal-LATIA closely correlated with those of the Fcal-ELISA (Spearman rank correlation coefficient, r=0.84; P<0.0001). The values of Fcal for each assay and the FIT all significantly correlated with the MESs (Spearman rank correlation coefficient, Fcal-LATIA: r=0.58, Fcal-ELISA: r=0.55, and FIT: r=0.72). The mucosal healing predictability (determined by an MES of 0 alone) of the Fcal-LATIA, Fcal-ELISA, and FIT-LATIA with the cutoffs determined by receiver operating characteristic curve analysis was 0.79, 0.78, and 0.92 for sensitivity, respectively, and 0.78, 0.69, and 0.73 for specificity, respectively.
Conclusions
The performance of the novel Fcal-LATIA was equivalent to that of the conventional Fcal assay. Simultaneous measurements with FITs would promote the clinical relevance of fecal biomarkers in UC. -
Citations
Citations to this article as recorded by- Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening
Timothy McAuliffe, Joseph C. Anderson, Robin J. Larson, Douglas J. Robertson
Alimentary Pharmacology & Therapeutics.2024; 59(9): 1033. CrossRef - Evaluation of a faecal calprotectin method using the OC-SENSOR PLEDIA
Shane O’Driscoll, Carolyn Piggott, Sally C. Benton
Clinical Chemistry and Laboratory Medicine (CCLM).2022; 60(6): 901. CrossRef - International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
Ferdinando D'Amico, David T. Rubin, Paulo Gustavo Kotze, Fernando Magro, Britta Siegmund, Taku Kobayashi, Pablo A. Olivera, Peter Bossuyt, Lieven Pouillon, Edouard Louis, Eugeni Domènech, Subrata Ghosh, Silvio Danese, Laurent Peyrin‐Biroulet
United European Gastroenterology Journal.2021; 9(4): 451. CrossRef - Faecal Calprotectin in Assessment of Mucosal Healing in Adults with Inflammatory Bowel Disease: A Meta-Analysis
Mariusz A. Bromke, Katarzyna Neubauer, Radosław Kempiński, Małgorzata Krzystek-Korpacka
Journal of Clinical Medicine.2021; 10(10): 2203. CrossRef - Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease
Eriko Yasutomi, Toshihiro Inokuchi, Sakiko Hiraoka, Kensuke Takei, Shoko Igawa, Shumpei Yamamoto, Masayasu Ohmori, Shohei Oka, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Keita Harada, Masaki Furukawa, Kouichi Itoshima, Ken Okada, Fumio Otsuka,
Scientific Reports.2021;[Epub] CrossRef - Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
Eun Soo Kim
Gut and Liver.2021; 15(5): 637. CrossRef - Fecal calprotectin predicts complete mucosal healing in patients with ulcerative colitis: Systematic review and meta‑analysis
Zhongsheng Cao, Chenglong Ye, Lunan Li, Xiaoge Geng, Wensheng Pan, Jiyong Jing
World Academy of Sciences Journal.2021;[Epub] CrossRef - Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults
Małgorzata Krzystek-Korpacka, Radosław Kempiński, Mariusz Bromke, Katarzyna Neubauer
Diagnostics.2020; 10(6): 367. CrossRef - Prostaglandin E-Major Urinary Metabolite Predicts Relapse in Patients With Ulcerative Colitis in Clinical Remission
Natsuki Ishida, Kiichi Sugiura, Takahiro Miyazu, Satoshi Tamura, Satoshi Suzuki, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Clinical and Translational Gastroenterology.2020; 11(12): e00289. CrossRef - Prediction of treatment outcome and relapse in inflammatory bowel disease
Jun Kato, Takeichi Yoshida, Sakiko Hiraoka
Expert Review of Clinical Immunology.2019; 15(6): 667. CrossRef
- Systematic scoping review: Use of the faecal immunochemical test residual buffer to enhance colorectal cancer screening
- 8,308 View
- 245 Download
- 9 Web of Science
- 10 Crossref
- Microbiota
- Evaluation of commercial probiotic lactic cultures against biofilm formation by Cronobacter sakazakii
- Anubhav Jamwal, Kavita Sharma, Rajni Chauhan, Saurabh Bansal, Gunjan Goel
- Intest Res 2019;17(2):192-201. Published online December 3, 2018
- DOI: https://doi.org/10.5217/ir.2018.00106
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Cronobacter sakazakii, an emergent pathogen is considered as a major concern to infants and neonates fed on reconstituted powdered infant milk formula. In conjunction with many other factors, biofilm forming capacity adds to its pathogenic potential. In view of the facts that infants are at highest risk to C. sakazakii infections, and emerging antibiotic resistance among pathogens, it is imperative to evaluate probiotic cultures for their efficacy against C. sakazakii. Therefore, pure probiotic strains were isolated from commercial probiotic products and tested for their antimicrobial and anti-biofilm activities against C. sakazakii.
Methods
A total of 6 probiotic strains were tested for their antibiotic susceptibility followed by antimicrobial activity using cell-free supernatant (CFS) against C. sakazakii. The inhibitory activity of CFS against biofilm formation by C. sakazakii was determined using standard crystal violet assay and microscopic observations.
Results
All the probiotic strains were sensitive to ampicillin, tetracycline, vancomycin and carbenicillin whereas most of the strains were resistant to erythromycin and novobiocin. Four of the 6 probiotic derived CFS possessed antimicrobial activity against C. sakazakii at a level of 40 μL. A higher biofilm inhibitory activity (>80%) was observed at initial stages of biofilm formation with weaker activity during longer incubation upto 48 hours (50%–60%).
Conclusions
The study indicated the efficacy of isolated commercial probiotics strains as potential inhibitor of biofilm formation by C. sakazakii and could be further explored for novel bioactive molecules to limit the emerging infections of C. sakazakii. -
Citations
Citations to this article as recorded by- Investigating the effect of Lactiplantibacillus plantarum TW57-4 in preventing biofilm formation and expression of virulence genes in Listeria monocytogenes ATCC 19115
Arezou Rouhi, Fereshteh Falah, Marjan Azghandi, Behrooz Alizadeh Behbahani, Seyed Ali Mortazavi, Farideh Tabatabaei-Yazdi, Alireza Vasiee
LWT.2024; 191: 115669. CrossRef - Exploring Technological, Safety and Probiotic Properties of Enterococcus Strains: Impact on Rheological Parameters in Fermented Milk
Souraya Sakoui, Reda Derdak, Oana Lelia Pop, Dan Cristian Vodnar, Fatimazahra Jouga, Bernadette-Emőke Teleky, Boutaina Addoum, Elemér Simon, Ramona Suharoschi, Abdelaziz Soukri, Bouchra El Khalfi
Foods.2024; 13(4): 586. CrossRef - Determination of Antioxidant and Antimicrobial Activities of Cell-Free Supernatant (CFSKC27L) and Exopolysaccharide (EPSKC27L) obtained from Ligilactobacillus salivarius KC27L
Kübra Çelik, Zehranur Yuksekdag, Berat Çınar Acar, Filiz Kara
Tekirdağ Ziraat Fakültesi Dergisi.2024; 21(4): 928. CrossRef -
Limosilactobacillus fermentum
MYSY8, a Potential Probiotic Isolate from Fermented Rice Beverage for the Control of
Microsporum canis
Padur Ramachandra Vanitha, Divyashree Shivakumar, Shruthi Basavaraj, Adithi Gunduraj, Dhanuja Janardanachar, Deepthi BV, Marikunte Yanjarappa Sreenivasa
Food Biotechnology.2024; 38(3): 314. CrossRef -
Exploration of Antibiofilm Activities of Pediococci Strains Against Diarrheal Multi-Drug Resistant
E.coli
Strains
Gunjan Sadera, Anjali Jaglan, Ashwani Kumar, Teresa Requena, Rakesh Kumar, Aparna Parmar, Gunjan Goel
Food Biotechnology.2024; 38(4): 385. CrossRef - Multivariate analysis of structural and functional properties of fibres from apple pomace using different extraction methods
Rusli Fidriyanto, Brij Pal Singh, K. M. Manju, Yantyati Widyastuti, Gunjan Goel
Food Production, Processing and Nutrition.2023;[Epub] CrossRef - Antifungal activity of probiotic strain Lactiplantibacillus plantarum MYSN7 against Trichophyton tonsurans
P. R. Vanitha, Rakesh Somashekaraiah, S. Divyashree, Indranil Pan, M. Y. Sreenivasa
Frontiers in Microbiology.2023;[Epub] CrossRef - Synergistic combination of malic acid with sodium hypochlorite impairs biofilm of Cronobacter sakazakii
Rajni Chauhan, Savita Kumari, Gunjan Goel, Wamik Azmi
LWT.2022; 155: 112902. CrossRef - Antibacterial and Antibiofilm Effect of Cell-Free Supernatant of Lactobacillus brevis KCCM 202399 Isolated from Korean Fermented Food against Streptococcus mutans KCTC 5458
Jong Ha Kim, Hye Ji Jang, Na-Kyoung Lee, Hyun-Dong Paik
Journal of Microbiology and Biotechnology.2022; 32(1): 56. CrossRef - Selection of a Potential Synbiotic against Cronobacter sakazakii
ALFRED KE, VALERIA R. PARREIRA, JEFFREY M. FARBER, LAWRENCE GOODRIDGE
Journal of Food Protection.2022; 85(9): 1240. CrossRef - Black cherry fruit as a source of probiotic candidates with antimicrobial and antibiofilm activities against Salmonella
S. Divyashree, P.G Anjali, B.V. Deepthi, Rakesh Somashekaraiah, Walid Mottawea, Riadh Hammami, M.Y. Sreenivasa
South African Journal of Botany.2022; 150: 861. CrossRef - Anti-biofilm effect of the cell-free supernatant of probiotic Saccharomyces cerevisiae against Listeria monocytogenes
Yeon Jin Kim, Hwan Hee Yu, Ye Ji Song, Yeong Jin Park, Na-Kyoung Lee, Hyun-Dong Paik
Food Control.2021; 121: 107667. CrossRef - Probiotic properties of Lactobacillus casei – MYSRD 108 and Lactobacillus plantarum-MYSRD 71 with potential antimicrobial activity against Salmonella paratyphi
S. Divyashree, P.G. Anjali, Rakesh Somashekaraiah, M.Y. Sreenivasa
Biotechnology Reports.2021; 32: e00672. CrossRef - Intestinal microbiota and inflammatory bowel diseases
Chang Soo Eun
Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef - Current and Future Perspectives on the Role of Probiotics, Prebiotics, and Synbiotics in Controlling Pathogenic Cronobacter Spp. in Infants
Alfred Ke, Valeria R. Parreira, Lawrence Goodridge, Jeffrey M. Farber
Frontiers in Microbiology.2021;[Epub] CrossRef - Impairment of Cronobacter sakazakii and Listeria monocytogenes biofilms by cell-free preparations of lactobacilli of goat milk origin
Niharika Singh, Ravinder Kaur, Brij Pal Singh, Namita Rokana, Gunjan Goel, Anil Kumar Puniya, Harsh Panwar
Folia Microbiologica.2020; 65(1): 185. CrossRef The Battle of Probiotics and Their Derivatives Against Biofilms
Abolfazl Barzegari, Keyvan Kheyrolahzadeh, Seyed Mahdi Hosseiniyan Khatibi, Simin Sharifi, Mohammad Yousef Memar, Sepideh Zununi Vahed
Infection and Drug Resistance.2020; Volume 13: 659. CrossRef- Postbiotics against Pathogens Commonly Involved in Pediatric Infectious Diseases
Anastasia Mantziari, Seppo Salminen, Hania Szajewska, Jeadran Nevardo Malagón-Rojas
Microorganisms.2020; 8(10): 1510. CrossRef
- Investigating the effect of Lactiplantibacillus plantarum TW57-4 in preventing biofilm formation and expression of virulence genes in Listeria monocytogenes ATCC 19115
- 9,836 View
- 307 Download
- 18 Web of Science
- 18 Crossref
- Colorectal neoplasia
- Clinical features and outcomes in spontaneous intramural small bowel hematoma: cohort study and literature review
- Eun Ae Kang, Seung Jun Han, Jaeyoung Chun, Hyun Jung Lee, Hyunsoo Chung, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyun Chae Jung
- Intest Res 2019;17(1):135-143. Published online October 10, 2018
- DOI: https://doi.org/10.5217/ir.2018.00085
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Spontaneous intramural small bowel hematoma (SISBH) is an extremely rare complication of anticoagulant or antiplatelet therapy. We assessed the clinical characteristics and outcomes of patients with SISBH according to the anatomical location of the hematoma.
Methods
From January 2003 to February 2016, medical records for all patients hospitalized for SISBH at 2 tertiary referral hospitals were retrospectively reviewed. The primary outcome was requirement for surgery.
Results
A total of 37 patients were enrolled. The mean age was 74.1 years. Among them, 33 patients (89.2%) were taking anticoagulant and/or antiplatelet agents. Duodenal intramural hematoma was detected in 4 patients (10.8%), jejunal in 16 (43.2%), and ileal in 17 (45.9%). Compared to jejunal and ileal involvement, duodenal intramural hematoma was significantly associated with high Charlson comorbidity index and low levels of white blood cells, hemoglobin, and platelets in the blood. SISBH in the duodenum was related to thrombocytopenia in 3 patients following systemic chemotherapy for malignancy. All patients with SISBH showed clinical improvement with conservative therapy. Mean length of hospital stay was 9.35 days. Independent predictors of a hospital stay of more than 7 days were body weight less than 60 kg (odds ratio [OR], 12.213; 95% confidence interval [CI], 1.755–84.998; P=0.011) and a history of cerebrovascular accidents (OR, 6.667; 95% CI, 1.121–39.650; P=0.037).
Conclusions
Compared to jejunal and ileal involvement, thrombocytopenia may result in spontaneous duodenal intramural hematoma among patients who are treated with systemic chemotherapy for malignancies. Patients with SISBH have excellent clinical outcomes with conservative therapy regardless of the anatomical location of the hematoma. -
Citations
Citations to this article as recorded by- A Case of Direct-Acting Oral Anticoagulant-Induced Intramural Colon Hematoma Successfully Treated by Laparoscopic Surgery
Daisuke Tomita, Shigeo Toda, Ryo Miyazaki, Shuichiro Matoba, Hiroya Kuroyanagi
Cureus.2024;[Epub] CrossRef - Spontaneous Intramural Small Bowel Hematoma in an Elderly Man with Multiple Myeloma
Sigrid L. Williamson, Aishwarya Suresh, Adrian Ong
The American Surgeon™.2023; 89(6): 2816. CrossRef - Intramural duodenal hematoma: diagnosis and management of a rare entity
Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
Cirugía Española (English Edition).2023; 101(7): 515. CrossRef - Hematoma intramural duodenal: diagnóstico y manejo de una entidad infrecuente
Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
Cirugía Española.2023; 101(7): 515. CrossRef - Jejunal intramural haematoma in a captive African lion (Panthera leo)
Richelle G. Butcher, Baukje Lenting, Alison S. Clarke, Kelly Buckle, Cristina Gans
Veterinary Record Case Reports.2023;[Epub] CrossRef - Spontaneous Duodenal Hematoma: A Rare Complication of Triple Antithrombotic Therapy Case Report
Mazin N Habhab, Asad J Torabi, Julie M Clary, George E Revtyak
Future Cardiology.2023; 19(2): 71. CrossRef - Intestinal Spontaneous Intramural Hematoma Secondary to Anticoagulation Therapy: A Case Report
Karim El Aidaoui, Wahib Lahlou, Abderrahim Bourial, Nawal Bouknani, Chafik El Kettani
Cureus.2023;[Epub] CrossRef - Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B
Wei-Jung Teng, Ching-Huei Kung, Mei-Mei Cheng, Jia-Ruey Tsai, Chia-Yau Chang
Journal of Clinical Medicine.2023; 12(9): 3093. CrossRef - Endoscopic management of intramural spontaneous duodenal hematoma: A case report
Giorgio Valerii, Vittorio Maria Ormando, Carlo Cellini, Luca Sacco, Carmelo Barbera
World Journal of Gastroenterology.2022; 28(20): 2243. CrossRef - Warfarin-induced spontaneous intramural small bowel hematoma presenting as an acute abdomen: A case report
Ding-Han Chen, Khay-Seng Soh, Ying-Tso Wang, Te-Chun Shen
Medicine.2022; 101(35): e30335. CrossRef - Spontaneous duodenal haematoma in a patient taking rivaroxaban
Rebeca de Barros Lopes, Finn McLennan Battleday, Toby Calvert, Rob Gwynne‐Jones, Rebecca Thomas
ANZ Journal of Surgery.2021;[Epub] CrossRef - SPONTANEOUS INTRAMURAL SMALL-BOWEL HEMATOMA: A CAUSE OF ACUTE ABDOMEN IN ANTICOAGULATED PATIENTS
Sergio Gil Rojas, Luis Miguel Estela Villa, Elsa María Jiménez Vicente
Revista Española de Enfermedades Digestivas.2021;[Epub] CrossRef - Small Bowel Obstruction
Allison A. Aka, Jesse P. Wright, Teresa DeBeche-Adams
Clinics in Colon and Rectal Surgery.2021; 34(04): 219. CrossRef - Double Trouble: Spontaneous Duodenal Hematoma of Pancreatic Origin
Luísa Martins Figueiredo, David Valadas Horta, Jorge A. Reis
GE - Portuguese Journal of Gastroenterology.2019; 26(6): 458. CrossRef
- A Case of Direct-Acting Oral Anticoagulant-Induced Intramural Colon Hematoma Successfully Treated by Laparoscopic Surgery
- 27,959 View
- 255 Download
- 17 Web of Science
- 14 Crossref
- Endoscopy
- Clinicopathological feature and treatment outcome of patients with colorectal laterally spreading tumors treated by endoscopic submucosal dissection
- Young-Hoon Jeong, Jun Lee, Sang-Wook Kim, Geom-Seog Seo, Hyun-Soo Kim, Young-Eun Joo
- Intest Res 2019;17(1):127-134. Published online October 10, 2018
- DOI: https://doi.org/10.5217/ir.2018.00075
-
Abstract
PDFPubReaderePub
- Background/Aims
Endoscopic submucosal dissection (ESD) is an advanced technique that can be used to treat precancerous and early colorectal neoplasms by facilitating en bloc resection regardless of tumor size. In our study, we investigated the clinicopathological feature and the treatment outcome of patients with colorectal laterally spreading tumors (LSTs) that were treated by ESD.
Methods
The study enrolled all of 210 patients with colorectal LSTs who underwent ESD. Clinical outcomes were analyzed by retrospectively reviewing medical records.
Results
A cancerous pit pattern (Vi/Vn) was more common in pseudo-depressed (PD) subtype than in flat elevated (FE) subtype. The incidence of adenocarcinoma in the PD subtype and nodular mixed (NM) subtypes was significantly higher than in the homogenous (HG) subtype and FE subtype. The en bloc and R0 resection rates were 89.0% and 85.7%, respectively. The bleeding and perforation rates were 5.2% and 1.9%, respectively. The mean procedure time was much longer in the PD subtype than in the FE subtype. The en bloc resection rate was significantly higher in the NM subtype than in the HG subtype. However, there were no statistically significant differences in mean procedure time, en bloc resection rate, R0 resection rate, bleeding rate, or perforation rate between LST-granular and LST-nongranular types.
Conclusions
These results indicate that ESD is acceptable for treating colorectal LSTs concerning en bloc resection, curative resection, and risk of complications. Careful consideration is required for complete resection of the PD subtype and NM subtype because of their higher malignant potential. -
Citations
Citations to this article as recorded by- Risk factors for unsuccessful colorectal endoscopic submucosal dissection: A systematic review and meta-analysis
Feng Gu, Wei Jiang, Jingyi Zhu, Lei Ma, Boyuan He, Huihong Zhai
Digestive and Liver Disease.2024; 56(8): 1288. CrossRef - Prognosis and risk factors of electrocoagulation syndrome after endoscopic submucosal dissection in the colon and rectum. Large cohort study
Seong-Jung Kim, Su Young Kim, Jun Lee
Surgical Endoscopy.2022; 36(8): 6243. CrossRef - Blue laser imaging combined with JNET (Japan NBI Expert Team) classification for pathological prediction of colorectal laterally spreading tumors
Si-lin Huang, Wen-xin Tan, Qun Peng, Wen-hua Zhang, Hai-tao Qing, Qiang Zhang, Jun Wu, Liang-dou Lin, Zhi-bin Lu, Yu Chen, Wei-guang Qiao
Surgical Endoscopy.2021; 35(10): 5430. CrossRef - Comparison of long-term recurrence-free survival between primary surgery and endoscopic resection followed by secondary surgery in T1 colorectal cancer
Eun Hye Oh, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Chang Sik Yu, Jin Cheon Kim, Jeong-Sik Byeon
Gastrointestinal Endoscopy.2021; 94(2): 394. CrossRef - Second-look endoscopy findings after endoscopic submucosal dissection for colorectal epithelial neoplasms
Soo-kyung Park, Hyeon Jeong Goong, Bong Min Ko, Haewon Kim, Hyo Sun Seok, Moon Sung Lee
The Korean Journal of Internal Medicine.2021; 36(5): 1063. CrossRef
- Risk factors for unsuccessful colorectal endoscopic submucosal dissection: A systematic review and meta-analysis
- 7,246 View
- 206 Download
- 6 Web of Science
- 5 Crossref
- Endoscopy
- The current capacity and quality of colonoscopy in Korea
- Jae Ho Choi, Jae Myung Cha, Jin Young Yoon, Min Seob Kwak, Jung Won Jeon, Hyun Phil Shin
- Intest Res 2019;17(1):119-126. Published online October 10, 2018
- DOI: https://doi.org/10.5217/ir.2018.00060
-
Abstract
PDFPubReaderePub
- Background/Aims
Little is known for the capacity and quality of colonoscopy, and adherence to colonoscopy surveillance guidelines in Korea. This study aimed to investigate the present and potential colonoscopic capacity, colonoscopic quality, and adherence to colonoscopy surveillance guidelines in Korea.
Methods
We surveyed representative endoscopists of 72 endoscopy units from June to August 2015, using a 36-item questionnaire regarding colonoscopic capacity, quality, and adherence to colonoscopy surveillance guidelines of each hospitals.
Results
Among the 62 respondents who answered the questionnaire, 51 respondents were analyzed after exclusion of 11 incomplete answers. Only 1 of 3 of endoscopy units can afford to perform additional colonoscopies in addition to current practice, and the potential maximum number of colonoscopies per week was only 42. The quality of colonoscopy was variable as reporting of quality indicators of colonoscopy were considerably variable (29.4%–94.1%) between endoscopy units. Furthermore, there are substantial gaps in the adherence to colonoscopy surveillance guidelines, as concordance rate for guideline recommendation was less than 50% in most scenarios.
Conclusions
The potential capacity and quality of colonoscopy in Korea was suboptimal. Considering suboptimal reporting of colonoscopic quality indicators and low adherence rate for colonoscopy surveillance guidelines, quality improvement of colonoscopy should be underlined in Korea. -
Citations
Citations to this article as recorded by- Trends in colorectal cancer incidence according to an increase in the number of colonoscopy cases in Korea
Ga Hee Kim, Yeong Chan Lee, Tae Jun Kim, Sung Noh Hong, Dong Kyung Chang, Young-Ho Kim, Dong-Hoon Yang, Chang Mo Moon, Kyunga Kim, Hyun Gun Kim, Eun-Ran Kim
World Journal of Gastrointestinal Oncology.2024; 16(1): 51. CrossRef - Factors Affecting Adherence to National Colorectal Cancer Screening: A 12-Year Longitudinal Study Using Multi-Institutional Pooled Data in Korea
Dae Sung Kim, Jeeyoung Hong, Kihyun Ryu, Sang Hyuk Lee, Hwanhyi Cho, Jehyeong Yu, Jieun Lee, Jong-Yeup Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef - Strategies to improve screening colonoscopy quality for the prevention of colorectal cancer
Joo Hye Song, Eun Ran Kim
The Korean Journal of Internal Medicine.2024; 39(4): 547. CrossRef - Faecal immunochemical tests can improve colonoscopy triage in patients with iron deficiency: A systematic review and meta-analysis
Jennifer Pham, Geraldine Laven-Law, Erin L. Symonds, Molla M. Wassie, Charles Cock, Jean M. Winter
Critical Reviews in Oncology/Hematology.2024; 201: 104439. CrossRef - Comparison of Synergistic Sedation with Midazolam and Propofol Versus Midazolam and Pethidine in Colonoscopies: A Prospective, Randomized Controlled Study
Jae Woong Lim, Min Jae Kim, Gang Han Lee, Dae Sol Kim, Sang Hyuk Jung, Yu Yeon Kim, Jin Won Kim, Yohan Lee, Hyun Soo Kim, Seon Young Park, Dong Hyun Kim
Chonnam Medical Journal.2024; 60(3): 192. CrossRef - Overview of the National Cancer Screening Program for Colorectal Cancer in Korea over 14 Years (2004-2017)
Bomi Park, Eun Young Her, Kyeongmin Lee, Fatima Nari, Jae Kwan Jun, Kui Son Choi, Mina Suh
Cancer Research and Treatment.2023; 55(3): 910. CrossRef - Sessile serrated lesions in patients with adenoma on index colonoscopy do not increase metachronous advanced adenoma risk
Seung Wook Hong, Jeongseok Kim, Ji Young Lee, Jong‐Soo Lee, Hye‐Sook Chang, Hye Won Park, Gwang‐Un Kim, Jiyoung Yoon, Byong Duk Ye, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Jaewon Choe, Dong‐Hoon Yang
Digestive Endoscopy.2022; 34(4): 850. CrossRef - Efficacy and safety of split-dose bowel preparation with 1 L polyethylene glycol and ascorbate compared with 2 L polyethylene glycol and ascorbate in a Korean population: a phase IV, multicenter, randomized, endoscopist-blinded study
Sung Noh Hong, Chang Kyun Lee, Jong Pil Im, Chang Hwan Choi, Jeong-Sik Byeon, Young-Seok Cho, Sung-Ae Jung, Tae Il Kim, Yoon Tae Jeen
Gastrointestinal Endoscopy.2022; 95(3): 500. CrossRef - Effect of colorectal cancer screening on long‐term survival of colorectal cancer patients: Results of the Korea National Cancer Screening Program
Xuan Quy Luu, Kyeongmin Lee, Jae Kwan Jun, Mina Suh, Kyu‐Won Jung, Kui Son Choi
International Journal of Cancer.2022; 150(12): 1958. CrossRef - A Study on Differences between Professional Endoscopists and Gastroenterologists in Endoscopic Detection and Standard Pathological Biopsy of Inflammatory Bowel Diseases
Dong Yang, Yuqin Li, Haibo Sun, Chuan He, Geng Chen, Zhuo Zhao, Tongyu Tang, Amosy M'Koma
Gastroenterology Research and Practice.2022; 2022: 1. CrossRef - Risk of Metachronous Colorectal Advanced Neoplasia and Cancer in Patients With 3–4 Nonadvanced Adenomas at Index Colonoscopy: A Systematic Review and Meta-Analysis
Suyeon Park, Seong Ran Jeon, Hyun Gun Kim, Yunho Jung, Min-Seob Kwak, Su Young Kim, Jong Wook Kim, Seung-Joo Nam, Eun Hye Oh, Seon-Young Park, Soo-Kyung Park, Jeong-Sik Byeon, Sun-Jin Boo, Dong Hoon Baek, Soon Man Yoon, Jaeyoung Chun, Jooyoung Lee, Miyoun
American Journal of Gastroenterology.2022; 117(4): 588. CrossRef - The Influence of Face Shields on the Quality of Colonoscopy in the Era of the COVID-19 Pandemic
Jin Wook Lee, Hyo Jeong Lee, Dae Sung Kim, Jiyoung Yoon, Seung Wook Hong, Ha Won Hwang, Jong-Soo Lee, Gwang-Un Kim, Sinwon Lee, Jaewon Choe, Jin Hwa Park, Dong-Hoon Yang, Jeong-Sik Byeon
Gut and Liver.2022; 16(3): 404. CrossRef - Quality indicators in colonoscopy: the chasm between ideal and reality
Su Bee Park, Jae Myung Cha
Clinical Endoscopy.2022; 55(3): 332. CrossRef - Intentions to undergo primary screening with colonoscopy under the National Cancer Screening Program in Korea
Kyeongmin Lee, Haejoo Seo, Sunho Choe, Seung-Yong Jeong, Ji Won Park, Mina Suh, Aesun Shin, Kui Son Choi, Filipe Prazeres
PLOS ONE.2021; 16(2): e0247252. CrossRef - Colonoscopy quality in community hospitals and nonhospital facilities in Korea
Jae Gon Lee, Dong Soo Han, Young-Eun Joo, Dae-Seong Myung, Dong Il Park, Seul Ki Kim, Yunho Jung, Won Hyun Lee, Eun Soo Kim, Joon Seok Yoon, Chang Soo Eun
The Korean Journal of Internal Medicine.2021; 36(Suppl 1): S35. CrossRef - Real-World National Colonoscopy Volume in Korea: A Nationwide Population-Based Study over 12 Years
Jae Myung Cha, Min Seob Kwak, Hyun-Soo Kim, Su Young Kim, Sohee Park, Geun U Park, Jung Kuk Lee, Soo Jin Kim, Hun Hee Lee, Joo Sung Kim, Won Ho Kim
Gut and Liver.2020; 14(3): 338. CrossRef
- Trends in colorectal cancer incidence according to an increase in the number of colonoscopy cases in Korea
- 12,877 View
- 172 Download
- 16 Web of Science
- 16 Crossref
- IBD
- Health-related quality of life of patients with inflammatory bowel disease in Singapore
- Prisca Yue Min Ho, Wenjia Hu, Ying Yun Lee, Chuxi Gao, Yan Zhi Tan, Hua Heng Cheen, Hwee Lin Wee, Teong Guan Lim, Wan Chee Ong
- Intest Res 2019;17(1):107-118. Published online November 12, 2018
- DOI: https://doi.org/10.5217/ir.2018.00099
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Inflammatory bowel disease (IBD) is associated with considerable impairment of patients’ health-related quality of life (HRQoL). Knowledge of factors that significantly affect IBD patients’ HRQoL can contribute to better patient care. However, the HRQoL of IBD patients in non-Western countries are limited. Hence, we assessed the HRQoL of Singaporean IBD patients and identified its determinants.
Methods
A prospective, cross-sectional study was conducted at Singapore General Hospital outpatient IBD Centre. The HRQoL of IBD patients was assessed using the short IBD questionnaire (SIBDQ), Short Form-36 physical and mental component summary (SF-36 PCS/MCS) and EuroQol 5-dimensions 3-levels (EQ-5D-3L) and visual analogue scale (VAS). Independent samples t-test was used to compare HRQoL between Crohn’s disease (CD) and ulcerative colitis (UC). Determinants of HRQoL were identified through multiple linear regression.
Results
A total of 195 IBD patients (103 UC, 92 CD) with a mean disease duration of 11.2 years were included. There was no significant difference in HRQoL between patients with UC and CD. Factors that significantly worsened HRQoL were presence of active disease (b=−6.293 [SIBDQ], −9.409 [PCS], −9.743 [MCS], −7.254 [VAS]), corticosteroids use (b=−7.392 [SIBDQ], −10.390 [PCS], −8.827 [MCS]), poor medication adherence (b=−4.049 [SIBDQ], −1.320 [MCS], −8.961 [VAS]), presence of extraintestinal manifestations (b=−13.381 [PCS]), comorbidities (b=−4.531 [PCS]), non-employment (b=−9.738 [MCS], −0.104 [EQ-5D-3L]) and public housing (b=−8.070 [PCS], −9.207 [VAS]).
Conclusions
The HRQoL is impaired in this Asian cohort of IBD. The magnitude of HRQoL impairment was similar in UC and CD. Clinical characteristics were better determinants of patients’ HRQoL than socio-demographic factors. Recognizing the factors that impact patients’ HRQoL would improve the holistic management of IBD patients. -
Citations
Citations to this article as recorded by- Psychometric Evaluation of the Bengali Short Form 12 Version 2 Health Survey in Patients With Inflammatory Bowel Disease
SM Ali Hasan, Chanchal K. Ghosh, Abdur R. Miah, Md Anwarul Kabir
Value in Health Regional Issues.2025; 45: 101036. CrossRef - Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations
Ágnes Eszter Tímár, Andrea Párniczky, Kinga Anna Budai, Márk Viktor Hernádfői, Emese Kasznár, Péter Varga, Péter Hegyi, Szilárd Váncsa, Réka Tóth, Dániel Sándor Veres, Miklós Garami, Katalin Eszter Müller
Journal of Crohn's and Colitis.2024; 18(6): 851. CrossRef - PSYCHO-EMOTIONAL STATUS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Viktoriya Romanukha, Olena Hryniv, Halyna Hvozdetska, Nadiia Baryla, Anna Hrushetska
Eastern Ukrainian Medical Journal.2024; 12(2): 202. CrossRef - Gut Microbiome and colorectal cancer: discovery of bacterial changes with metagenomics application in Turkısh population
Yakup Ulger, Anıl Delik, Hikmet Akkız
Genes & Genomics.2024; 46(9): 1059. CrossRef - Quality of life of inflammatory bowel diseases patients in france with EQ-5D-5 L: the QALY-MICI study
H. Sarter, J. Kirschgesner, L. Beaugerie, A. Buisson, C. Gower-Rousseau, Gérard de Pouvourville
Quality of Life Research.2024;[Epub] CrossRef - Impact of Nursing Interventions via Telephone and Email on the Quality of Life of Patients with Inflammatory Bowel Disease: Preliminary Results of a Comparative Observational Study
Caterina Mercuri, Vincenza Giordano, Vincenzo Bosco, Nicola Serra, Rocco Spagnuolo, Rita Nocerino, Teresa Rea, Carmen Colaci, Assunta Guillari, Patrizia Doldo, Silvio Simeone
Healthcare.2024; 12(24): 2538. CrossRef - Illness Identity in Inflammatory Bowel Disease
Jessica Rassart, Carine Van Wanseele, Lynn Debrun, Koen Matthijs, Philip Moons, Liesbet Van Bulck, Seher Arat, Lukas Van Oudenhove, Koen Luyckx
International Journal of Behavioral Medicine.2023; 30(1): 77. CrossRef - How the interplay among the tumor microenvironment and the gut microbiota influences the stemness of colorectal cancer cells
María Belén Novoa Díaz, Pedro Carriere, Claudia Gentili
World Journal of Stem Cells.2023; 15(5): 281. CrossRef - Quality of Life of Patients With Inflammatory Bowel Disease in Bangladesh
Chanchal Kumar Ghosh, Sumona Islam, Nowrin Tabassum, Syed Arafat Mohiuddin, Md. Mosarrof Hossain, Aditi Sarkar, Amit Bari
Cureus.2023;[Epub] CrossRef - Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study
Hassan Karami, Farbod Ebadi Fard Azar, Kamran Bagheri Lankarani, Aziz Rezapour, Sulmaz Ghahramani, Abdolvahab Baghbanian
Current Drug Safety.2023; 18(4): 484. CrossRef - Health‐related quality of life aspects of the ‘Periodontitis prevalence in ulcerative colitis and Crohn's disease’ (PPCC) cohort
Kristina Bertl, Georgios Tsakos, Nikolaos Pandis, Anna Bogren, Johan Burisch, Andreas Stavropoulos
Journal of Clinical Periodontology.2023; 50(12): 1601. CrossRef - The impact of gastrointestinal conditions on psychosocial factors associated with the biopsychosocial model of health: A scoping review
Elizabeth Dent, Nicola Davinson, Stephanie Wilkie
Applied Psychology: Health and Well-Being.2022; 14(2): 626. CrossRef - Health-related quality of life among Chinese patients with Crohn’s disease: a cross-sectional survey using the EQ-5D-5L
Ziyun Gao, Pei Wang, Jie Hong, Yuqing Yan, Tianying Tong, Bin Wu, Jun Hu, Zhenhua Wang
Health and Quality of Life Outcomes.2022;[Epub] CrossRef - Health-Related Quality of Life of Patients Treated with Biological Agents and New Small-Molecule Drugs for Moderate to Severe Crohn’s Disease: A Systematic Review
Hasan Aladraj, Mohamed Abdulla, Salman Yousuf Guraya, Shaista Salman Guraya
Journal of Clinical Medicine.2022; 11(13): 3743. CrossRef - Landscape of inflammatory bowel disease in Singapore
Daren Low, Nidhi Swarup, Toshiyuki Okada, Emiko Mizoguchi
Intestinal Research.2022; 20(3): 291. CrossRef - Daily life difficulties among patients with ulcerative colitis in Japan and the United Kingdom: A comparative study
Aki Kawakami, Makoto Tanaka, Kayoko Sakagami, Lee Meng Choong, Reiko Kunisaki, Shin Maeda, Ingvar Bjarnason, Hiroaki Ito, Bu’Hussain Hayee
Medicine.2022; 101(35): e30216. CrossRef - Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study
Romina di Giuseppe, Sandra Plachta-Danielzik, Wolfgang Mohl, Martin Hoffstadt, Thomas Krause, Bernd Bokemeyer, Stefan Schreiber
International Journal of Colorectal Disease.2021; 36(11): 2445. CrossRef - Burden of Inflammatory Bowel Disease on Patient Mood, Fatigue, Work, and Health-Related Quality of Life in Thailand: A Case-Control Study
Kasenee Tiankanon, Julajak Limsrivilai, Napapat Poocharoenwanich, Phutthaphorn Phaophu, Nichcha Subdee, Natanong Kongtub, Satimai Aniwan
Crohn's & Colitis 360.2021;[Epub] CrossRef - Microbe-based management for colorectal cancer
Zi-Yun Gao, Zhe Cui, Yu-Qing Yan, Li-Jun Ning, Zhen-Hua Wang, Jie Hong
Chinese Medical Journal.2021; 134(24): 2922. CrossRef - Comparison of Disease-related Knowledge of Patients With Inflammatory Bowel Disease Between the West and the East Using an Updated Questionnaire (IBD-KNOW)
Jin Yong Kim, Hyuk Yoon, Jun Seong Hwang, Suk-Kyun Yang, Sang Hyoung Park, Edward V. Loftus
Journal of Clinical Gastroenterology.2020; 54(8): 720. CrossRef - Observational study on the evaluation of quality of life in patients affected by enteropathic spondyloarthritis
Maria Sole Chimenti, Paola Conigliaro, Barbara Polistena, Paola Triggianese, Arianna D'Antonio, Benedetto Neri, Giorgia Sena, Federico Spandonaro, Livia Biancone, Roberto Perricone
Musculoskeletal Care.2020; 18(4): 527. CrossRef - Key patient related factors in the management of inflammatory bowel disease
Eleonora Allocati, Brian Godman
Journal of Medical Economics.2020; 23(12): 1606. CrossRef - The prevalence and risk factors of psychological disorders, malnutrition and quality of life in IBD patients
Qin Cao, Yu-Hong Huang, Min Jiang, Cong Dai
Scandinavian Journal of Gastroenterology.2019; 54(12): 1458. CrossRef
- Psychometric Evaluation of the Bengali Short Form 12 Version 2 Health Survey in Patients With Inflammatory Bowel Disease
- 10,049 View
- 249 Download
- 26 Web of Science
- 23 Crossref
- IBD
- Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
- Rintaro Moroi, Katsuya Endo, Katsutoshi Yamamoto, Takeo Naito, Motoyuki Onodera, Masatake Kuroha, Yoshitake Kanazawa, Tomoya Kimura, Yoichi Kakuta, Atsushi Masamune, Yoshitaka Kinouchi, Tooru Shimosegawa
- Intest Res 2019;17(1):94-106. Published online December 3, 2018
- DOI: https://doi.org/10.5217/ir.2018.00048
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Few reports have described the long-term treatment outcomes of the anti-tumor necrosis factor-α antibody for Japanese Crohn’s disease (CD) patients. The aim of this study was to evaluate them and clarify the clinical factors that affect the long-term prognosis of the anti-tumor necrosis factor-α treatments.
Methods
This was a retrospective, observational, single-center cohort study. Japanese CD patients treated with either infliximab or adalimumab as a first-line therapy were analyzed. The cumulative retention rates of the biologics, relapse-free survival, and surgery-free survival were analyzed using Kaplan-Meier methods. The clinical factors associated with the long-term outcomes were estimated by both the log-rank test and Cox proportional hazard model.
Results
The cumulative retention rate was significantly higher in the group with a concomitant elemental diet of ≥900 kcal/day, baseline C-reactive protein (CRP) levels <2.6 mg/dL, and baseline serum albumin levels ≥3.5 g/dL, respectively. The baseline serum albumin levels were also associated with both relapse-free and surgery-free survival. The lack of concomitant use of an elemental diet ≥900 kcal/day was identified as the only independent risk factor for the withdrawal of the biologics.
Conclusions
Baseline CRP levels and serum albumin levels could affect the long-term outcomes in CD patients. Concomitant elemental diet of ≥900 kcal/day could have a positive influence on clinical treatment course. -
Citations
Citations to this article as recorded by- Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
Marco Valvano, Annalisa Capannolo, Nicola Cesaro, Gianpiero Stefanelli, Stefano Fabiani, Sara Frassino, Sabrina Monaco, Marco Magistroni, Angelo Viscido, Giovanni Latella
Nutrients.2023; 15(17): 3824. CrossRef - Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
Haruka Otake, Satohiro Matsumoto, Hirosato Mashima
Intestinal Research.2022; 20(4): 464. CrossRef - Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - C-reactive protein is associated with postoperative outcomes in patients with intestinal Behçet’s disease
Eun Ae Kang, Jung Won Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Min Soo Cho, Jae Hee Cheon
BMC Gastroenterology.2021;[Epub] CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef - Efficacy of enteral nutrition in patients with Crohn’s disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis
Fumihito Hirai, Teruyuki Takeda, Yasumichi Takada, Masahiro Kishi, Tsuyoshi Beppu, Noritaka Takatsu, Masaki Miyaoka, Takashi Hisabe, Kenshi Yao, Tosiharu Ueki
Journal of Gastroenterology.2020; 55(2): 133. CrossRef - TL1A (TNFSF15) genotype affects the long‐term therapeutic outcomes of anti‐TNFα antibodies for Crohn's disease patients
Katsuya Endo, Yoichi Kakuta, Rintaro Moroi, Katsutoshi Yamamoto, Hisashi Shiga, Masatake Kuroha, Takeo Naito, Yoshitaka Kinouchi, Atsushi Masamune
JGH Open.2020; 4(6): 1108. CrossRef
- Nutrition, Nutritional Status, Micronutrients Deficiency, and Disease Course of Inflammatory Bowel Disease
- 7,626 View
- 244 Download
- 8 Web of Science
- 8 Crossref
- IBD
- Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients
- Keiji Yagisawa, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Takahiko Toyonaga, Miki Miura, Mari Hayashida, Eiko Saito, Masaru Nakano, Hajime Matsubara, Tadakazu Hisamatsu, Toshifumi Hibi
- Intest Res 2019;17(1):87-93. Published online December 14, 2018
- DOI: https://doi.org/10.5217/ir.2018.00078
- Correction in: Intest Res 2020;18(3):343
-
Abstract
PDFPubReaderePub
- Background/Aims
Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabilities of these formulations may influence patient adherence; however, they have not been compared to date. This study aimed to evaluate the acceptabilities of the 2 formulations of CR mesalazine in relation to patient adherence using a crossover questionnaire survey.
Methods
UC patients were randomly assigned to 2 groups in a 1:1 ratio. Patients in each group took either 4 g of CR mesalazine tablets or granules for 6 to 9 weeks, and then switched to 4 g of the other formulation for a further 6 to 9 weeks. The acceptability and efficacy were evaluated by questionnaires, and adherence was assessed using a visual analog scale. The difference in acceptabilities between the 2 formulations and its impact on adherence were assessed.
Results
A total of 49 patients were prospectively enrolled and 33 patients were included in the analysis. Significantly more patients found the tablets to be less acceptable than the granules (76% vs. 33%, P=0.0005). The granules were preferable to the tablets when the 2 formulations were compared directly (73% vs. 21%, P=0.004), for their portability, size, and numbers of pills. The adherence rate was slightly better among patients taking the granules (94% vs. 91%) during the observation period, but the difference was not significant (P=0.139).
Conclusions
CR mesalazine granules are more acceptable than tablets, and may therefore be a better option for long-term medication. -
Citations
Citations to this article as recorded by- Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef - A review on taste masked multiparticulate dosage forms for paediatric
Khater AL-Japairai, Samah Hamed Almurisi, Abd Almonem Doolaanea, Syed Mahmood, Fawaz Alheibshy, Ahmed Alobaida, Nadiya Abdul-Halim, Bappaditya Chatterjee
International Journal of Pharmaceutics.2023; 632: 122571. CrossRef - Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey
Xavier Hébuterne, Stephan R Vavricka, Helen C Thorne, Lara MacKenzie-Smith, Raphaël Laoun, Johan Burisch
Inflammatory Intestinal Diseases.2023; 8(1): 41. CrossRef - Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis
Xinyi Guo, Changxing Liu, Yahui Huang, Naeem Jan
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef - Factors Associated with Self-reported Medication Adherence in Japanese Community-dwelling Elderly Individuals: The Nakajima Study
Natsuko Ishida, Yurina Tokumoto, Yukio Suga, Moeko Noguchi-Shinohara, Chiemi Abe, Sohshi Yuki-Nozaki, Ayaka Mori, Mai Horimoto, Koji Hayashi, Kazuo Iwasa, Masami Yokogawa, Mai Ishimiya, Hiroyuki Nakamura, Kiyonobu Komai, Ryo Matsushita, Junko Ishizaki, Ma
YAKUGAKU ZASSHI.2021; 141(5): 751. CrossRef - Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef - Association of Self-Reported Medication Adherence with Potentially Inappropriate Medications in Elderly Patients: A Cross-Sectional Pilot Study
Motoyasu Miyazaki, Masanobu Uchiyama, Yoshihiko Nakamura, Koichi Matsuo, Chika Ono, Miwa Goto, Ayako Unoki, Akio Nakashima, Osamu Imakyure
International Journal of Environmental Research and Public Health.2020; 17(16): 5940. CrossRef - Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
Satoshi Tamura, Natsuki Ishida, Takahiro Miyazu, Shunya Onoue, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Scientific Reports.2020;[Epub] CrossRef
- Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
- 8,800 View
- 348 Download
- 9 Web of Science
- 9 Crossref
- IBD
- Efficacy of fecal microbiota therapy in steroid dependent ulcerative colitis: a real world intention-to-treat analysis
- Ajit Sood, Ramit Mahajan, Garima Juyal, Vandana Midha, Charanpreet Singh Grewal, Varun Mehta, Arshdeep Singh, Mohan C Joshi, Vikram Narang, Kirandeep Kaur, Hasrat Sidhu
- Intest Res 2019;17(1):78-86. Published online November 20, 2018
- DOI: https://doi.org/10.5217/ir.2018.00089
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Four high-quality randomized controlled trials have proven the efficacy of fecal microbiota transplantation (FMT) in active ulcerative colitis (UC). We assessed the efficacy of FMT in a real-world setting involving steroid-dependent patients with UC.
Methods
This was a single-center prospective analysis of data from steroid-dependent patients with UC treated with FMT from September 2015 to September 2017 at the Dayanand Medical College, a tertiary care center in India. Fecal samples from random unrelated donors were administered through colonoscopy at weeks 0, 2, 6, 10, 14, 18, and 22. The primary outcome was achievement of steroid-free clinical remission, and the secondary outcomes were clinical response and endoscopic remission at 24 weeks. Modified intention-to-treat analysis was performed, which included subjects who underwent at least 1 FMT.
Results
Of 345 patients with UC treated during the study period, 49 (14.2%) had steroid-dependent UC. Of these 49 patients, 41 underwent FMT: 33 completed 7 sessions over 22 weeks according to the protocol, and 8 discontinued treatment (non-response, 5; lost to follow-up, 2; and fear of adverse effects, 1). At week 24, steroid-free clinical remission was achieved in 19 out of 41 (46.3%) patients, whereas clinical response and endoscopic remission were achieved in 31 out of 41 (75.6%) and 26 out of 41 (63.4%) patients, respectively. All patients with clinical response were able to withdraw steroids. There were no serious adverse events necessitating discontinuation.
Conclusions
A multisession FMT via the colonoscopic route is a promising therapeutic option for patients with steroid-dependent UC, as it can induce clinical remission and aid in steroid withdrawal. -
Citations
Citations to this article as recorded by- The practice of fecal microbiota transplantation in inflammatory bowel disease
Umang Arora, Saurabh Kedia, Vineet Ahuja
Intestinal Research.2024; 22(1): 44. CrossRef - Current perspectives on fecal microbiota transplantation in inflammatory bowel disease
Arshdeep Singh, Vandana Midha, Nar Singh Chauhan, Ajit Sood
Indian Journal of Gastroenterology.2024; 43(1): 129. CrossRef - Artemisia argyi polyphenols Attenuates DSS-induced colitis in mice by regulating the structural composition of gut microbiota
Huaqiang Zhang, Zhonghua Hao, Ruya Zhang, Jiang Tong, Xiaoke Wang, Jingjing Liu, Yingkui Gao, Xuefang Wang, Qing Su, Haojie Wen, Yi Fan, Fang Liu, Xiao Li, Chao Tong, Xuebing Wang
Phytomedicine.2024; 132: 155897. CrossRef - Perception of fecal microbiota transplantation in patients with ulcerative colitis in Korea: a KASID multicenter study
Jebyung Park, Sung Noh Hong, Hong Sub Lee, Jongbeom Shin, Eun Hye Oh, Kwangwoo Nam, Gyeol Seong, Hyun Gun Kim, Jin-Oh Kim, Seong Ran Jeon
The Korean Journal of Internal Medicine.2024; 39(5): 783. CrossRef - Fecal transplantation for treatment of inflammatory bowel disease
Aamer Imdad, Natasha G Pandit, Muizz Zaman, Nathan Zev Minkoff, Emily E Tanner-Smith, Oscar G Gomez-Duarte, Sari Acra, Maribeth R Nicholson
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef - Single-Donor and Pooling Strategies for Fecal Microbiota Transfer Product Preparation in Ulcerative Colitis: Systematic Review and Meta-Analysis
Benoît Levast, Mathieu Fontaine, Stéphane Nancey, Pierre Dechelotte, Joël Doré, Philippe Lehert
Clinical and Translational Gastroenterology.2023;[Epub] CrossRef - Lithium carbonate alleviates colon inflammation through modulating gut microbiota and Treg cells in a GPR43-dependent manner
Shengjie Huang, Shiping Hu, Shuang Liu, Bo Tang, Yaojiang Liu, Li Tang, Yuanyuan Lei, Li Zhong, Shiming Yang, Song He
Pharmacological Research.2022; 175: 105992. CrossRef - Gut microbiota in inflammatory bowel disease: a target for therapy not to be missed
Tiziana LARUSSA, Ludovico ABENAVOLI, Giulia FABIANO, Maria A. MANCUSO, Natale POLIMENI, Dan L. DUMITRASCU, Francesco LUZZA
Minerva Gastroenterology.2022;[Epub] CrossRef - Fecal microbiota transplantation for induction of remission, maintenance and rescue in patients with corticosteroid-dependent ulcerative colitis: a long-term follow-up real-world cohort study
Avnish Kumar Seth, Priti Jain
Intestinal Research.2022; 20(2): 251. CrossRef - Systematic review of donor and recipient predictive biomarkers of response to faecal microbiota transplantation in patients with ulcerative colitis
Nia Paddison Rees, Walaa Shaheen, Christopher Quince, Chris Tselepis, Richard D Horniblow, Naveen Sharma, Andrew D Beggs, Tariq H Iqbal, Mohammed Nabil Quraishi
eBioMedicine.2022; 81: 104088. CrossRef - An updated systematic review and meta-analysis of fecal microbiota transplantation for the treatment of ulcerative colitis
Taobi Huang, Jinlan Xu, Maoying Wang, Ke Pu, Longquan Li, Huiyun Zhang, Yuan Liang, Weiming Sun, Yuping Wang
Medicine.2022; 101(30): e29790. CrossRef - Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
Soo-Kyung Park, Sang-Bum Kang, SangSoo Kim, Tae Oh Kim, Jae Myung Cha, Jong Pil Im, Chang Hwan Choi, Eun Soo Kim, Geom Seog Seo, Chang Soo Eun, Dong Soo Han, Dong Il Park
The Korean Journal of Internal Medicine.2022; 37(5): 949. CrossRef - Early fecal microbiome transfer after donor defecation determines response in patients with moderate to severe ulcerative colitis
Arshdeep Singh, Ramit Mahajan, Bhavjeet Kaur Kahlon, Ashvin Singh Dhaliwal, Vandana Midha, Varun Mehta, Namita Bansal, Dharmatma Singh, Ajit Sood
Indian Journal of Gastroenterology.2022; 41(4): 389. CrossRef - Physician education can minimize inappropriate steroid use in patients with inflammatory bowel disease: the ACTION study
Yehyun Park, Chang Hwan Choi, Hyun Soo Kim, Hee Seok Moon, Do Hyun Kim, Jin Ju Kim, Dennis Teng, Dong Il Park
Intestinal Research.2022; 20(4): 452. CrossRef - Inflammatory bowel disease in India: challenges and opportunities
Alice Snell, Jonathan Segal, Jimmy Limdi, Rupa Banerjee
Frontline Gastroenterology.2021; 12(5): 390. CrossRef - Clinical Predictors of Response to Faecal Microbiota Transplantation in Patients with Active Ulcerative Colitis
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Kirandeep Kaur, Dharmatma Singh, Namita Bansal, Khushdeep Dharni
Journal of Crohn's and Colitis.2021; 15(2): 238. CrossRef - Long-term efficacy and safety of monotherapy with a single fresh fecal microbiota transplant for recurrent active ulcerative colitis: a prospective randomized pilot study
Haiming Fang, Lian Fu, Xuejun Li, Chunxia Lu, Yuan Su, Kangwei Xiong, Lijiu Zhang
Microbial Cell Factories.2021;[Epub] CrossRef - Repeated Fecal Microbial Transplantations and Antibiotic Pre-Treatment Are Linked to Improved Clinical Response and Remission in Inflammatory Bowel Disease: A Systematic Review and Pooled Proportion Meta-Analysis
Valentin Mocanu, Sabitha Rajaruban, Jerry Dang, Janice Y. Kung, Edward C. Deehan, Karen L. Madsen
Journal of Clinical Medicine.2021; 10(5): 959. CrossRef - Efficacy and Safety of Fecal Microbiota Transplantation and Prospect of Microbe-based Therapies for Inflammatory Bowel Disease
Hoon Gil Jo, Geom Seog Seo
The Korean Journal of Gastroenterology.2021; 78(1): 31. CrossRef - Intestinal microbiota and inflammatory bowel diseases
Chang Soo Eun
Journal of the Korean Medical Association.2021; 64(9): 588. CrossRef - The Role of Glucocorticoids in Inflammatory Diseases
Sybille D. Reichardt, Agathe Amouret, Chiara Muzzi, Sabine Vettorazzi, Jan P. Tuckermann, Fred Lühder, Holger M. Reichardt
Cells.2021; 10(11): 2921. CrossRef - Acceptability, tolerability, and safety of fecal microbiota transplantation in patients with active ulcerative colitis (AT&S Study)
Ajit Sood, Arshdeep Singh, Ramit Mahajan, Vandana Midha, Varun Mehta, Yogesh Kumar Gupta, Vikram Narang, Kirandeep Kaur
Journal of Gastroenterology and Hepatology.2020; 35(3): 418. CrossRef - Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening
Ting Zhang, Gaochen Lu, Zhe Zhao, Yafei Liu, Quan Shen, Pan Li, Yaoyao Chen, Haoran Yin, Huiquan Wang, Cicilia Marcella, Bota Cui, Lei Cheng, Guozhong Ji, Faming Zhang
Protein & Cell.2020; 11(4): 251. CrossRef - Efficacy of intestinal microbiota transplantation in ulcerative colitis: a review of current literature and knowledge
Krista M. Newman, Byron P. Vaughn
Minerva Gastroenterologica e Dietologica.2020;[Epub] CrossRef - Advances in the understanding of the intestinal micro-environment and inflammatory bowel disease
Peng-Guang Yan, Jing-Nan Li
Chinese Medical Journal.2020; 133(7): 834. CrossRef - Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment
Xiao Yan Guo, Xin Juan Liu, Jian Yu Hao
Journal of Digestive Diseases.2020; 21(3): 147. CrossRef - Enhancing patient adherence to fecal microbiota transplantation maintains the long-term clinical effects in ulcerative colitis
Qianqian Li, Ting Zhang, Xiao Ding, Liyuan Xiang, Bota Cui, Heena Buch, Faming Zhang
European Journal of Gastroenterology & Hepatology.2020; 32(8): 955. CrossRef - Incidental benefits after fecal microbiota transplant for ulcerative colitis
Ramit Mahajan, Vandana Midha, Arshdeep Singh, Varun Mehta, Yogesh Gupta, Kirandeep Kaur, Ritu Sudhakar, Anmol Singh Pannu, Dharmatma Singh, Ajit Sood
Intestinal Research.2020; 18(3): 337. CrossRef - Fecal Microbiota Transplantation for Ulcerative Colitis: The Optimum Timing and Gut Microbiota as Predictors for Long-Term Clinical Outcomes
Qianqian Li, Xiao Ding, Kangjian Liu, Cicilia Marcella, Xiaolin Liu, Ting Zhang, Yafei Liu, Pan Li, Liyuan Xiang, Bota Cui, Jun Wang, Jianling Bai, Faming Zhang
Clinical and Translational Gastroenterology.2020; 11(8): e00224. CrossRef - Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
Luciane de Fátima Caldeira, Helena H. Borba, Fernanda S. Tonin, Astrid Wiens, Fernando Fernandez-Llimos, Roberto Pontarolo, Udai P. Singh
PLOS ONE.2020; 15(9): e0238910. CrossRef - Efficacy and safety of fecal microbiota transplantation by washed preparation in patients with moderate to severely active ulcerative colitis
Min Chen, Xiao Lei Liu, Yu Jie Zhang, Yong Zhan Nie, Kai Chun Wu, Yong Quan Shi
Journal of Digestive Diseases.2020; 21(11): 621. CrossRef - Fecal Microbiota Transplantation for Ulcerative Colitis: An Evolving Therapy
Ajit Sood, Arshdeep Singh, Vandana Midha, Ramit Mahajan, Dina Kao, David T Rubin, Charles N Bernstein
Crohn's & Colitis 360.2020;[Epub] CrossRef - Efficacy and safety of fecal microbiota transplantation for treating patients with ulcerative colitis: A systematic review and meta‐analysis
Hai Lan Zhao, Shu Zhen Chen, Hao Ming Xu, You Lian Zhou, Jie He, Hong Li Huang, Jing Xu, Yu Qiang Nie
Journal of Digestive Diseases.2020; 21(10): 534. CrossRef - Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia
Siew C Ng, Joyce Wing Yan Mak, Partha Pal, Rupa Banerjee
The Lancet Gastroenterology & Hepatology.2020; 5(12): 1089. CrossRef - Lithium Carbonate Treatment Alleviates Gut Inflammation Through Activating Treg Cell Responses in a Microbiota-Dependent Manner
Shengjie Huang, Bo Tang, Li Tang, Yaojiang Liu, Shuang Liu, Yuanyuan Lei, Shiping Hu, Li Zhong, Shiming Yang, Song He
SSRN Electronic Journal .2020;[Epub] CrossRef - Fecal Microbiota Transplantation in Intestinal Disorders: A Primer for Physicians
Ajit Sood, Vandana Midha, Harmeet Kaur, Arshdeep Singh
Journal of Gastrointestinal Infections.2020; 10(1): 16. CrossRef - Multi-session fecal microbiota transplantation using colonoscopy has favorable outcomes for the treatment of
steroid-dependent ulcerative colitis
Young-Seok Cho
Intestinal Research.2019; 17(1): 6. CrossRef - Intestinal microbiome as a novel therapeutic target for local and systemic inflammation
Kazuhiko Uchiyama, Yuji Naito, Tomohisa Takagi
Pharmacology & Therapeutics.2019; 199: 164. CrossRef - Role of Faecal Microbiota Transplantation for Maintenance of Remission in Patients With Ulcerative Colitis: A Pilot Study
Ajit Sood, Ramit Mahajan, Arshdeep Singh, Vandana Midha, Varun Mehta, Vikram Narang, Tarundeep Singh, Anmol Singh Pannu
Journal of Crohn's and Colitis.2019; 13(10): 1311. CrossRef - Evolution of fecal microbiota transplantation in methodology and ethical issues
Faming Zhang, Ting Zhang, Heming Zhu, Thomas J Borody
Current Opinion in Pharmacology.2019; 49: 11. CrossRef
- The practice of fecal microbiota transplantation in inflammatory bowel disease
- 9,750 View
- 276 Download
- 41 Web of Science
- 40 Crossref
- IBD
- Vitamin D deficiency is associated with disease activity in patients with Crohn’s disease
- Kyoung Ho Ko, You Sun Kim, Bo Kyung Lee, Jong Hyun Choi, Yong Moon Woo, Jin Young Kim, Jeong Seop Moon
- Intest Res 2019;17(1):70-77. Published online October 10, 2018
- DOI: https://doi.org/10.5217/ir.2018.00022
-
Abstract
PDFPubReaderePub
- Background/Aims
Previous data suggest that vitamin D has a significant role in inflammatory bowel disease (IBD). We investigated the incidence of vitamin D deficiency in Korean patients with IBD and the correlation between serum vitamin D level and disease activity.
Methods
We retrospectively analyzed the medical records of patients with IBD whose serum vitamin D levels were checked. Deficiency of 25-hydroxyvitamin D was defined as <20 ng/mL. Disease activity was evaluated using the partial Mayo score for ulcerative colitis (≥2 defined as active disease) and Harvey-Bradshaw index for Crohn’s disease (≥4 defined as active disease).
Results
We enrolled 87 patients with IBD (ulcerative colitis [UC], 45; Crohn’s disease [CD], 42). Among them, 65.5% (57/87) were men, with a mean age of 44.9±15.1 years (range, 18–75 years). The mean duration of disease was 4.7±4.8 years (range, 0.1–17.1 years). Vitamin D deficiency was found in 73.6% (64/87) of patients with IBD. Patients with IBD (mean vitamin D level, 16.3±9.0 ng/mL) showed lower vitamin D level than the healthy control group (mean vitamin D level, 20.4±7.0 ng/mL), with no statistically significant difference (P=0.136). Disease activity was inversely correlated with vitamin D deficiency in patients with CD (P=0.007). However, no correlation was observed in patients with UC (P=0.134).
Conclusions
Approximately 75% of Korean patients with IBD showed vitamin D deficiency state. Vitamin D deficiency is associated with disease activity, particularly in patients with CD. -
Citations
Citations to this article as recorded by- Correlation of Socioeconomic and Environmental Factors With Incidence of Crohn Disease in Children and Adolescents: Systematic Review and Meta-Regression
Jens Weidner, Ingmar Glauche, Ulf Manuwald, Ivana Kern, Ines Reinecke, Franziska Bathelt, Makan Amin, Fan Dong, Ulrike Rothe, Joachim Kugler
JMIR Public Health and Surveillance.2024; 10: e48682. CrossRef - Micronutrient Deficiency and Muscular Status in Inflammatory Bowel Disease
Joonhee Han, Hyun Joo Song, Min Sook Kang, Hogyung Jun, Heung Up Kim, Ki Soo Kang, Donghyoun Lee
Nutrients.2024; 16(21): 3763. CrossRef - Is Serum 25-Hydroxyvitamin D Level Associated with Severity of COVID-19? A Retrospective Study
Munachimso Kizito Mbata, Mireille Hunziker, Anja Makhdoomi, Giorgia Lüthi-Corridori, Maria Boesing, Stéphanie Giezendanner, Jürgen Muser, Anne B. Leuppi-Taegtmeyer, Jörg D. Leuppi
Journal of Clinical Medicine.2023; 12(17): 5520. CrossRef - Genotype Prevalence of Lactose Deficiency, Vitamin D Deficiency, and the Vitamin D Receptor in a Chilean Inflammatory Bowel Disease Cohort: Insights from an Observational Study
Tamara Pérez-Jeldres, M. Bustamante, Roberto Segovia-Melero, Nataly Aguilar, Fabien Magne, Gabriel Ascui, Denisse Uribe, Lorena Azócar, Cristián Hernández-Rocha, Ricardo Estela, Verónica Silva, Andrés De La Vega, Elizabeth Arriagada, Mauricio Gonzalez, Gi
International Journal of Molecular Sciences.2023; 24(19): 14866. CrossRef - The correlation between serum 25-hydroxyvitamin D level and ulcerative colitis: a systematic review and meta-analysis
Chenyu Liu, Xin Liu, Haitao Shi, Fenrong Chen, Linlang Sun, Xin Gao, Yan Wang
European Journal of Gastroenterology & Hepatology.2023; 35(12): 1375. CrossRef - Prevalence and relevant factors of micronutrient deficiencies in hospitalized patients with inflammatory bowel disease
Xiaojuan Li, Yedong Hu, Xiaodan Shi, Xinyan Zhu, Fei Liu
Nutrition.2022; 99-100: 111671. CrossRef - The Role of Vitamin D in Immune System and Inflammatory Bowel Disease
Zengrong Wu, Deliang Liu, Feihong Deng
Journal of Inflammation Research.2022; Volume 15: 3167. CrossRef - Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intestinal Research.2022; 20(3): 321. CrossRef - The Crosstalk between Vitamin D and Pediatric Digestive Disorders
Cristina Oana Mărginean, Lorena Elena Meliț, Reka Borka Balas, Anca Meda Văsieșiu, Tudor Fleșeriu
Diagnostics.2022; 12(10): 2328. CrossRef - Intestinal vitamin D receptor signaling ameliorates dextran sulfate sodium‐induced colitis by suppressing necroptosis of intestinal epithelial cells
Yongyan Shi, Xuewei Cui, Yanli Sun, Qun Zhao, Tianjing Liu
The FASEB Journal.2020; 34(10): 13494. CrossRef Relationship Between Vitamin D Deficiency and Disease Activity in Patients with Inflammatory Bowel Disease in Ahvaz, Iran
Esmat Rasouli, Narges Sadeghi, Abazar Parsi, Seyed Jalal Hashemi, Morteza Nayebi, Aliakbar Shayesteh
Clinical and Experimental Gastroenterology.2020; Volume 13: 419. CrossRef- Inflammatory Bowel Disease and Vitamin D
Ki Bae Kim, Hyoung Woo Kim, Jun Su Lee, Soon Man Yoon
The Korean Journal of Gastroenterology.2020; 76(6): 275. CrossRef - Implications of the Westernized Diet in the Onset and Progression of IBD
Fernando Rizzello, Enzo Spisni, Elisabetta Giovanardi, Veronica Imbesi, Marco Salice, Patrizia Alvisi, Maria Chiara Valerii, Paolo Gionchetti
Nutrients.2019; 11(5): 1033. CrossRef - Vitamin D deficiency associated with Crohn’s disease and ulcerative colitis: a meta-analysis of 55 observational studies
Xi-Xi Li, Yang Liu, Jie Luo, Zhen-Dong Huang, Chao Zhang, Yan Fu
Journal of Translational Medicine.2019;[Epub] CrossRef - Vitamin D Deficiency is Associated with Increased Disease Activity in Patients with Inflammatory Bowel Disease
Johannes Hausmann, Alica Kubesch, Mana Amiri, Natalie Filmann, Irina Blumenstein
Journal of Clinical Medicine.2019; 8(9): 1319. CrossRef - The Association of Disease Activity, BMI and Phase Angle with Vitamin D Deficiency in Patients with IBD
Maria Chiara Mentella, Franco Scaldaferri, Marco Pizzoferrato, Antonio Gasbarrini, Giacinto Abele Donato Miggiano
Nutrients.2019; 11(11): 2583. CrossRef
- Correlation of Socioeconomic and Environmental Factors With Incidence of Crohn Disease in Children and Adolescents: Systematic Review and Meta-Regression
- 7,891 View
- 305 Download
- 19 Web of Science
- 16 Crossref
- IBD
- Hypoalbuminemia as a risk factor for thromboembolic events in inflammatory bowel disease inpatients
- Marcello Rabello Imbrizi, Daniela Oliveira Magro, Tirzah de Mendonça Lopes Secundo, Marlone Cunha-Silva, Paulo Gustavo Kotze, Ciro Garcia Montes, Jazon Romilson de Souza Almeida, Virgínia Lúcia Ribeiro Cabral
- Intest Res 2019;17(1):63-69. Published online January 25, 2019
- DOI: https://doi.org/10.5217/ir.2018.00077
-
Abstract
PDFPubReaderePub
- Background/Aims
Inflammatory bowel disease (IBD) are chronic entities characterized by local and systemic inflammation and may be associated with thrombosis. The aim of this study was to identify the prevalence of thromboembolic events (TEE) in hospitalized IBD patients and identify risk factors for their occurrence.
Methods
This retrospective, single-center study included patients treated at a Brazilian IBD referral unit between 2004 and 2014. Patients hospitalized for more than 48 hours due to active IBD and who did not receive prophylaxis for TEE during hospitalization were included. Patients were allocated to 2 groups: those with TEE up to 30 days or at the time of hospitalization (TEE-group) and patients without TEE (control-group). Clinical and laboratory characteristics were evaluated.
Results
Of 53 patients evaluated, 69,8% with Crohn’s disease (CD) and 30.2% with ulcerative colitis (UC). The prevalence of TEE 30 days before or during hospitalization was 15.1%, with 10.8% in CD and 25% in UC. In the TEE group, mean serum albumin was 2.06 g/dL versus 3.30 g/dL in the control group. Patients with albumin levels below 2.95 g/dL (43.18%) had a higher risk of developing TEE (relative risk, 1.72; 95% confidence interval, 1.17–2.53) (P<0.001).
Conclusions
Albumin levels were significantly lower in patients with TEE, and hypoalbuminemia was considered a risk factor for the development of TEE in this population. -
Citations
Citations to this article as recorded by- Experience of primary intestinal lymphangiectasia in adults: Twelve case series from a tertiary referral hospital
Ji Eun Na, Ji Eun Kim, Sujin Park, Eun Ran Kim, Sung Noh Hong, Young-Ho Kim, Dong Kyung Chang
World Journal of Clinical Cases.2024; 12(4): 746. CrossRef - Risk of venous thromboembolism with a central venous catheter in hospitalized Japanese patients with inflammatory bowel disease: a propensity score-matched cohort study
Yasuhiro Aoki, Hiroki Kiyohara, Yohei Mikami, Kosaku Nanki, Takaaki Kawaguchi, Yusuke Yoshimatsu, Shinya Sugimoto, Tomohisa Sujino, Kaoru Takabayashi, Naoki Hosoe, Haruhiko Ogata, Yasushi Iwao, Takanori Kanai
Intestinal Research.2023; 21(3): 318. CrossRef - Predictors of Deep Venous Thrombosis in Hospitalized Patients With Liver Cirrhosis in the US
Ahmad Abou Yassine, Mohammad Abureesh, Rachelle Hamadi, Loai Dahabra, Mohammad Alshami, Deeb Liliane
Cureus.2022;[Epub] CrossRef - Venous Thromboembolism Risk in Asian Patients with Inflammatory Bowel Disease: A Population-Based Nationwide Inception Cohort Study
Su Young Kim, Yeon Seo Cho, Hyun-Soo Kim, Jung Kuk Lee, Hee Man Kim, Hong Jun Park, Hyunil Kim, Jihoon Kim, Dae Ryong Kang
Gut and Liver.2022; 16(4): 555. CrossRef - Thromboembolism is associated with poor prognosis and high mortality in patients with inflammatory bowel disease: A case–control study
Yadukrishna S., Saurabh Kedia, Varun Teja, Sudheer Kumar Vuyyuru, Nidhi Yadav, Pabitra Sahu, Saransh Jain, Dawesh P. Yadav, Sawan Bopanna, Venigalla Pratap Mouli, Deepak Madhu, Raju Sharma, Prasenjit Das, Govind Makharia, Vineet Ahuja
Indian Journal of Gastroenterology.2022;[Epub] CrossRef - Coagulation status, fibrinolysis, and platelet dynamics in dogs with chronic inflammatory enteropathy
Sara A. Jablonski Wennogle, Christine S. Olver, Sarah B. Shropshire
Journal of Veterinary Internal Medicine.2021; 35(2): 892. CrossRef - Hypoalbuminemia: a risk factor in patients with STEC-associated hemolytic uremic syndrome
Carlos J. Cobeñas, Laura L. Lombardi, Priscila Pereyra, Emanuel De Rose, María José Gogorza, Ana Paula Spizzirri, Javier D. Ruscasso, Soledad Luján Ferradas, Ángela del Carmen Suárez, Oscar R. Amoreo, Javier H. Zalba, Paula Risso
Pediatric Nephrology.2021; 36(9): 2739. CrossRef - A Conceptual Framework for Rescheduling Elective Pediatric Gastroenterology Procedures Following COVID-19 Pandemic Lockdown
Panamdeep Kaur, Thomas M. Attard, Douglas S. Fishman, Fernando Zapata, Donna Ditsch, Mike Thomson, Jennifer V. Schurman
Gastroenterology Nursing.2020; 43(5): 375. CrossRef - SURGICAL STRATEGIES IN MULTIDISCIPLINARY MANAGEMENT OF CROHN'S DISEASE
Claudio Saddy Rodrigues Coy, Paulo Gustavo Kotze
Revista Médica Clínica Las Condes.2019; 30(5): 349. CrossRef
- Experience of primary intestinal lymphangiectasia in adults: Twelve case series from a tertiary referral hospital
- 7,207 View
- 178 Download
- 9 Web of Science
- 9 Crossref
First
Prev
